UNIVERSITY OF BIRMINGHAM

Research at Birmingham

Potential environmental implications of nano-enabled medical applications:

Mahapatra, Indrani; Clark, Julian; Dobson, Peter J.; Owen, Richard; Lead, Jamie R.

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
Mahapatra, I, Clark, J, Dobson, PJ, Owen, R & Lead, JR 2013, 'Potential environmental implications of nano-enabled medical applications: critical review', Environmental Science Processes and Impacts , vol. 15, no. 1, pp. 123-144. https://doi.org/10.1039/C2EM30640A

Link to publication on Research at Birmingham portal

Potential environmental implications of nano-enabled medical applications: critical review

Indrani Mahapatra,[a] J. Clark,[a] Peter J. Dobson,[b] Richard Owen[c] and Jamie R. Lead[*ad]

The application of nanotechnology and nanoscience for medical purposes is anticipated to make significant contributions to enhance human health in the coming decades. However, the possible future mass production and use of these medical innovations exhibiting novel and multifunctional properties will very likely lead to discharges into the environment giving rise to potentially new environmental hazards and risks. To date, the sources, the release form and environmental fate and exposure of nano-enabled medical products have not been investigated and little or no data exists, although there are a small number of currently approved medical applications and a number in clinical trials. This paper discusses the current technological and regulatory landscape and potential hazards and risks to the environment of nano-enabled medical products, data gaps and gives tentative suggestions relating to possible environmental hotspots.

Environmental impact

The application of nanotechnology in healthcare is emerging as an important strategic area of research and it is likely to make significant contributions to improving healthcare in coming decades. However, the likely emergence of large scale nanomedicine production is likely to lead to significant environmental exposure of bioactive and potentially toxic nanomaterials. The bioactive nature of these materials might lead to enhanced risk *e.g.* in enhanced 'Trojan Horse' type mechanisms in drug delivery vehicles. By controlling exposure and/or by designing drugs effectively with environmental concerns in mind will maximize benefit and minimize risk. In order to prompt a discussion of this emerging area, this review presents the current status of nanomedicine developments, brings together the knowledge from the field of environment impact research of pharmaceuticals and nanomaterials and the existing regulatory guidelines to identify knowledge gaps and uncertainties which need to be addressed to ensure a safe, sustainable and effective technology is produced and used.

Introduction

Nanotechnology is a large, convergent, multidisciplinary enabling field that is rapidly growing.[1,2] Size dependent properties due to spatial confinement along with their high specific surface area and surface energies, give nanomaterials (NMs) unique, size dependent and tuneable electronic and optical behaviour. Such properties can be exploited in a range of applications including in nanomedicine,† which also utilise other nanoscale properties such as their ability to interact with the cellular machinery and potential for targeted cellular and sub-cellular compartmentalization.[3,4] Applications of nanotechnology in healthcare can be as platforms for drug delivery, for enhancing outcomes of various treatment types such as photothermal therapy, thermal ablation and hyperthermia treatments, *in vitro* detection of biomarkers, imaging, and as combined drug and diagnostics devices – "theranostics" (for more details, see ref. 5–8).

Applications of nanotechnology can increase the efficacy of therapeutics by providing solutions to the traditional problems associated with pharmaceutical solubility,[9] limiting systemic toxicities,‡[10] bioavailability,[12] immunocompatibility[13] and cellular uptake.[14] Nanotechnology based therapeutics can be produced either through top down processes such as milling, high pressurised homogenisation, etching, lithography and other methods, or through bottom up processes, such as chemical synthesis both for inorganic NMs or complex polymeric designs to act as therapeutic agents or carriers of therapeutic agents.§ These nanocarriers¶ can be used to encapsulate and/or conjugate therapeutic agents like pDNA, siRNA and traditional chemotherapeutics (*e.g.*, paclitaxel, doxorubicin,

[a]*School of Geography, Earth and Environmental Sciences, University of Birmingham, Birmingham, B15 2TT, UK. E-mail: j.r.lead@bham.ac.uk*

[b]*Begbroke Science Park, University of Oxford, Begbroke, OX5 1PF, UK*

[c]*Business School, University of Exeter, Exeter, EX4 4PU, UK*

[d]*Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina 29208, USA*

† The terms nanomedicine, nano-enabled medical products and nano-enabled medical applications have been used interchangeably in the text.

‡ Systemic toxicity refers to adverse effects on any organ system following absorption and distribution of a chemical throughout the body (see ref. 11).

§ Therapeutic agents can be small molecule drugs, biotechnology derived products *e.g.*, cell, oligonucleotides, monoclonal antibodies, polymers, and vaccines. The terms therapeutics agents, pharmaceuticals and drugs has been used interchangeably in the text.

¶ Sometimes called nanovectors or drug delivery systems/vehicles or nanoconstructs.

This journal is © The Royal Society of Chemistry 2013

Environ. Sci.: Processes Impacts, 2013, **15**, 123–144 | **123**

irinotecan)[9,15–17] which have had limited applications in clinical settings due to biological degradation, high systemic toxicities or other factors. Additionally, functionalization of the surface of these NMs using aptamers, antibodies, and cell receptor recognising proteins helps to achieve targeted drug delivery.

Nano-enabled *in vitro* diagnostic devices can help in the detection and early diagnosis of diseases like cancer (*e.g.*, see a recent review, ref. 18) with increased sensitivity[19] and in a non-invasive manner.[20] In addition to *in vitro* diagnostics,

nanotechnology is being used to develop new MRI contrast agents for *in vivo* diagnostics for contrast enhancement. For instance, a ten-fold increase in MRI contrast in comparison to clinical Gd(III) contrast agents *e.g.* Gd–DTPA and Gd–DOTA was observed by using nanodiamond conjugated to Gadolinium(III) [Gd(III)–ND].[21] Due to these advantages, research and development investment of nanotechnology and nanomedicine has increased rapidly over the last 10 years, and it is likely that production and use of nano-enabled medical applications will rise in the coming years.

A recent, detailed study has estimated that there are currently 247 nanomedical products that have been approved and are in the market or are in early or late stages of clinical trials, with many more in development.[22] A market research firm, BCC research, has estimated that the nanomedical global market value increased from USD 53 billion in 2009 to USD 72.8 billion in 2011. Additionally, the firm has projected a compound annual growth rate in the global market for nanomedicines to be 12.5%, between the years 2011 and 2016, with largest growth in the therapeutic area of oncology and disorders of the central nervous system (CNS).[23,24] The applications currently in clinical development belong to the categories of liposomal formulations, polymer–protein and polymer–drug conjugates, micelles, antibody–drug conjugates, dendrimers, metal and metal oxide NMs. Please see Table 1 exemplifying each of these categories.

Indrani Mahapatra has worked in the areas of health risk assessment due to industrial and indoor air pollution, corporate sustainability reporting and assurance, corporate sustainable sourcing strategies, hazardous waste issues and management, and implementation of renewable energy projects at community level. She has a Master's in Environment Management and is currently pursuing Ph.D. at University of Birmingham, U.K.

J. Clark is Senior Lecturer in Geography at University of Birmingham. His research focuses on political geographies of Europe, the political governance of natural resources, and the interrelations between political geography and political science. He has published widely on political geography and environmental governance and has research monographs published by Oxford University Press and Routledge-Cavendish.

Peter J. Dobson currently holds the position of Academic Director at Begbroke Science Park, University of Oxford and is the Chief Strategic Advisor on Nanotechnology to the Research Councils in the UK. His research interests primarily lies in the areas of most aspects of nanotechnology with focus on applications to medicine. He founded two spin-off two companies, Oxonica plc and Oxford Biosensors Ltd., in the decade of 1990–2000. He was named the Innovator of the Year in 2005 by the Small Times Magazine. He advises several corporate and government organisations on nanotechnology and knowledge transfer.

Richard Owen holds the Chair in Responsible Innovation at the University of Exeter Business School, where he is Director of Postgraduate Research. Richard's research involves understanding the responsible emergence of innovation and new technologies in democratic society, with a particular emphasis on governance. Richard is a member of EPSRC's Strategic Advisory Network where he advises on societal and ethical issues.

Jamie Lead is the Chair in Environmental Nanoscience and Risk and Director of the SmartState Center for Environmental Nanoscience and Risk for at University of South Carolina, U.S.A and adjunct Professor of Environmental Nanoscience and Founder and Co-Director of the Facility for Environmental Nanoscience and Characterisation at the University of Birmingham, UK. His research interests cover nano-scale phenomena in environmental systems, including natural and manufactured materials, their interactions, chemistry, fate and effects, risk and regulation.

Table 1 Examples of nano-enabled medical applications (in market and in development)

Details	Nanocomponent (size)	Drug or device	Reference
Diagnosis of lung cancer, breast, colon cancer, gastric lesions, *etc.* and multiple sclerosis from biomarkers in exhaled breath	Gold NPs (5 nm), SWCNT	Device	20 and 52–56
Alkylated polyethylenimine (PEI) nanoparticles (NPs) incorporated in composite resin dental restorative materials to reduce bacterial infections and dental caries	PEI NPs	Device	57
Obturators lined with silicon incorporated with quaternary ammonium polyethylenimine (PEI) NPs for managing post surgery infection in head and neck cancer	PEI NPs	Device	58
Liposomal formulation of two anti-leishmaniasis drugs for treatment of leishmaniasis	Liposome	Drug	59
Liposome formulation of combination anticancer drugs: • cytarabine and daunorubicin for acute myeloid leukemia • irinotecan and floxuridine for colorectal cancer	Liposome	Drug	60
Chemotherapeutic drug (paclitaxel) associated albumin nanoparticles used as last line treatment for metastatic breast cancer	Albumin NPs (130 nm)	Drug	61
Chemotherapeutic drug doxorubicin associated with polyethylene glycol (PEG) liposomes	PEGylated liposomes	Drug	62
• PEGylated interferons + drug for treatment of hepatitis C • methoxy PEGylated erythropoietin receptor activators for anaemic patients with chronic kidney disease or myeloma • monoclonal antibody directed against TNF-α with a PEG tail for treatment of rheumatoid arthritis and Crohn's disease	PEGylated proteins	Drug	Summarised in ref. 5, see also ref. 63
Thermosensitive liposome in combination with doxorubicin and radiofrequency ablation or hyperthermia or high intensity focussed ultrasound for treatment of breast cancer, colorectal liver and bone metastases	Thermosensitive liposome	Drug	64–66
Chemotherapeutic drug paclitaxel in polymeric micelles for treatment of breast cancer, lung cancer, advanced ovarian cancer	PEG and poly(D,L-lactic acid) polymeric micelle	Drug	41 and 67
Anticancer drugs paclitaxel, cisplatin and oxaliplatin in polymeric micelles	Polymeric micelle	Drug	68
Radioactive Yttrium-90 conjugated with monoclonal antibody directed against CD40 antigen of B cells for treatment of relapsed or refractory, low-grade, follicular or B-cell non Hodgkin's lymphoma (nuclear medicine or biotech medicine)	—	Drug	Summarised in ref. 5
Circulating tumour cells test/assay for diagnosis of metastatic breast, colorectal or prostate cancer: ferro-magnetic NPs labelled with monoclonal antibodies corresponding to specific antigen expressed in cancer cells	Magnetic nanoparticles	Device	69
Infectious disease tests, cardiac tests, *etc.* using gold NPs functionalised with specific biomolecules like oligonucleotides, antibodies	Gold NPs (13–20 nm)	Device	70
Fifth generation PAMAM dendrimers used for immunoassays as confirmation test for the occurrence of myocardial ischemia	Dendrimers	Device	71 and 72
Mannosylated polyethylenimine (PEI) polymers containing plasmid DNA as therapeutic vaccine for HIV/AIDS	PEI polymers	Device (the delivery patch)	17 and 73
A fourth generation L-lysine dendrimer with naphthalene disulfonic acid surface groups in a gel base for treatment of bacterial vaginosis, coating of condoms for sexually transmitted diseases, *etc.*	Lysine dendrimer	Drug	74 and 75
PEGylated colloidal gold bound TNF for treatment of advanced solid tumors	Gold NPs (~27 nm)	Drug	76
Gold coated silica nanoparticles for thermal ablation of refractory head and neck cancer	Au–Si NP (150 nm)	Device	77

This journal is © The Royal Society of Chemistry 2013

Environ. Sci.: Processes Impacts, 2013, **15**, 123–144 | **125**

Table 1 (Contd.)

Details	Nanocomponent (size)	Drug or device	Reference
Bio bar code assay: it has a magnetic micro particle plate functionalised with target specific recognition agents (in this case monoclonal anti-PSA antibodies) and the second component is AuNP probes, average 30 nm size, carrying hundreds of DNA strands and PSA strands leading to amplification of the signal. Detection of prostate cancer relapse post-prostatectomy	AuNP probes (average 30 nm)	Device	19
Superparamagnetic iron oxide nanoparticles as contrast agents for delineating the bowel, glioblastoma multiforme, lymph nodes in prostate cancer	Iron oxide NPs[a]	Drug	78–80
Iron oxide nanoparticles coated with polyglucose sorbitol carboxymethyl ether for treatment of iron deficiency anaemia in chronic kidney disease	Iron oxide NPs (30 nm with coating)	Drug	81 and 82
SPIONs (superparamagnetic iron oxide NPs) for tracking of inflammatory (mononuclear) cells	Iron oxide NPs[a]	Drug	83
SPIONS with aminosilane coating for treatment of multiforme glioblastoma (an aggressive brain cancer) in combination with application of external magnetic field	∼15 nm iron oxide NPs	Device	84
Silver nanoparticles associated with wound dressings	Nanocrystalline silver	Device	85
Nano silver hand gel	Nanosilver	Drug	86
Nano silver impregnated activated carbon wound dressing	Nanosilver	Drug and device combination	87
Nano silver coated latex central venous catheters to reduce chances of infections	Nanosilver	Device	88

[a] Though the exact sizes are not known here, superparamagnetic and ultrasuperparamagnetic iron oxide nanoparticles are mainly made of γ Fe_2O_3 and Fe_3O_4 and have core diameter <25 nm (see ref. 89) and 5–12 nm (cited in ref. 90) respectively. These magnetic particles are coated with silica, dextran, *etc.* for specific applications.

Only a few earlier publications to date have discussed potential issues related to nanotoxicity of nanomedicine and the majority of these have drawn extensively upon from the literature relating specifically to health impacts of fine particulates.[25–28] Occupational exposure from nanomedical applications and ways of monitoring was discussed by Murashov.[29] To the best of our knowledge, Baun and Hansen[30] were the first to publish their perspective specifically regarding nanomedicine and the environment. These early statements of problem formulation strongly suggest the need for research on ecotoxicology, environmental exposures and risks. Subsequently, a handful of empirical studies have been published in this area (see Table 3). Additionally, the European Medicines Agency in 2010 conducted a workshop on nanomedicines and had a discussion on specific methodological issues for environmental risk assessment of nanomedicines.[31] However, concrete steps are yet to be taken in this area. The nascent stage of the nanomedicine field, the assumption that more targeted medicines will reduce dosages, and that safety issues are covered in the stringent and well controlled development pathway of therapeutics are all reasons for this lack of action in this area. However, assumptions for pharmaceuticals have previously been made, *e.g.*, that their small amount compared to other chemicals would not pose any risk and that pharmaceutical industries follow good manufacturing practices, but the current environmental research focusing on pharmaceuticals indicates that problems are arising.[32] In addition, a number of other issues are pertinent: (1) it is appropriate to consider these issues at an early stage before development is 'locked' in by economic and other factors, (2) targeting will increase solubility and bioavailability in the environment even though medical dosages used might be low and (3) stringent regulatory controls are evident in the human area but less so for environmental exposure and behaviour. Therefore, it is appropriate to critically review the available information in this area, understand the knowledge gaps and address this potential issue at an early stage.

In this review, we discuss (i) the existing status of definitions of nanomedicine and a few relevant examples of nanomedicines under development, (ii) the current status of knowledge regarding environmental hazards and risks of conventional pharmaceuticals and nanomaterials with a view to understanding the environmental risks of nanomedicines, (iii) existing regulatory framework for pharmaceuticals for human use and medical devices and its coverage in the context of nanomedical applications and (iv) uncertainties and knowledge gaps.

This paper focuses on nanomedical applications which are marketed or are in advanced stages of clinical development. The nanomedical applications that find mention in the text belong to the category of therapeutics and diagnostics. Developments and clinical applications in regenerative nanomedicine are excluded in this review. There are a large number of proof-of-concept works related to nanocarriers based on fullerenes, carbon nanotubes, nanodiamonds, graphene, *etc.* which have immense potential for a myriad of applications in drug delivery. However, to the best of the knowledge of the authors, disease treatment strategies which have shown potential either *in vitro* or in proof-of-concept

experiments using these materials are yet to move beyond pre-clinical stage, therefore, this paper doesn't focus on these materials. A lot of ecotoxicity research has been conducted on quantum dots (CdTe/CdSe as core), but these ecotoxicity studies are not being reviewed here because the use of quantum dots is not directly related to clinical applications. Of course, quantum dots are used in life sciences for cell imaging, tracking and elucidating biochemical mechanisms, hence they are important for medical research and innovation, but they are beyond the scope of this review. There is only one *in vitro* diagnostic device in the clinical trial phase which possibly uses SWCNT (single walled carbon nanotube), therefore, this paper also doesn't focus on the ecotoxicity research conducted on carbon nanotubes. The governance and regulatory framework explained in the text is EU centric and the paper refrains from touching upon other regulatory guidelines existing beyond the EU, unless exceptionally necessary to explain a particular section.

Nanotechnology in healthcare applications

The aim of nanomedicine is the comprehensive monitoring, repair and improvement of all human biological systems, working from the molecular level using engineered devices and nanostructures to achieve medical benefit. The concept includes nanoscale active components or objects ranging in size from 1 nm to 100s of nm.[33] The European Commission's recommendation on the definition of nanomaterial creates a special case for pharmaceuticals and medical devices. The recommendation mentions that the proposed size cut-off value of 1 to 100 nm, with more than 50% of particles by number in this range, should not prejudice pharmaceutical and the medical devices sectors.[34] Thus, though mainstream nanotechnology explores particles between 1 and 100 nm in diameter, for nanomedicine, the size of the nanomaterials might in totality exceed 100 nm. The US FDA is yet to define nanomaterial or nanomedicine. Therefore, a widely accepted and clear definition is essential for appropriate regulation of nanomedicine but is not in place as yet due to novelty and multidisciplinarity of the field and broad range of applications that can be developed in the context of other convergent technologies. Nevertheless, rapid progress towards a definition is essential for regulatory purposes.

Nanomaterials are broadly classified into two categories based on the type of interactions exploited for designing nanomedicine. These two categories are 'hard' and 'soft'. Hard nanomaterials are metal and metal oxide nanoparticles, fullerenes, *etc.* formed *via* ionic or covalent bonds, whereas 'soft' nanocarriers use weak interactions.[35] The key types of hard nanomaterials currently being investigated for clinical applications and in the market are AgNPs, AuNPs and Fe_xO_y NPs. AgNPs has an antimicrobial effect and finds it uses in bandages for burn injuries, catheters and others. The potential for AuNPs in biomedical applications is due to its surface chemistry which makes it amenable to coating and functionalising with various targeting ligands, relative biocompatibility and photo-optical properties.[36] Fe_xO_y NPs are used because at nanoscale iron oxide exhibits super-paramagnetism and can be used as contrast agents as well as for hyperthermia

treatments for cancer.[37,38] Formulating metal and metal oxide NMs of different sizes and surface coating can help develop various biomedical applications.

The key types of 'soft' nanocarriers in the market or in advanced stages of development are:

● *Liposomes* are spherical vesicles composed of amphiphilic phospholipids and cholesterol, which self-assemble into bilayers to encapsulate an aqueous interior. They are one of the oldest and widely recognised nanocarriers and they can serve as a platform for delivery of both hydrophilic and hydrophobic therapeutic agents (see ref. 39 and references therein). Liposomes vary greatly in size from 25 nm to 5000 nm (ref. 40) and can be classified in terms of composition and mechanism of intracellular delivery into five types: conventional liposomes, pH-sensitive liposomes, cationic liposomes, immunoliposomes, and long-circulating or PEGylated liposomes.[41]

● *Dendrimers* are synthetic polymers (*e.g.* polyamidoamine, polypropylene imine) in which the atoms are arranged in many branches and sub-branches radiating out from a central core and sizes can be in the nm to μm range. Dendrimers can be categorized based on the number of the branches they possess which are called generations (G1, G2, G3, *etc.*). Dendrimers are being identified as ideal nanoscale drug delivery systems due their capacity to carry multiple modalities (therapeutic, imaging, and targeting). A plethora of different dendrimer compositions and chemical surface modifications can be synthesized and dendrimers can themselves act as therapeutic agents (for further details, see ref. 42–44).

● *Micelles* are nanosized, spherical colloidal particles with a hydrophobic interior (core) and a hydrophilic exterior (shell). Drugs or contrast agents may be entrapped within the hydrophobic core or linked covalently to the surface of micelles (for examples, see ref. 45).

Nanocarrier design requirements: The key principles governing rational design considerations of nanocarriers are:[46,47]

● physiologically stable nanocarriers capable of evading the reticuloendothelial system/mononuclear phagocytic system

● amenability to surface functionalisation with targeting moieties such as antibodies and cell penetrating peptides

● ability to cross the biological barriers of the body

● availability of a clearance mechanism that does not harm other organs

● ability to release the drug payload at the required site (delivery can also be designed so that it is modulated by pH or redox changes, enzymatic cleavage of bonds or activated by external stimulus such as electro-magnetic fields)

● biodegradability and biocompatibility, *i.e.*, low or no immunotoxic, genotoxic, mutagenic, reproductive and developmental toxic effect for human beings.

These design features of nanocarriers will have the potential to increase therapeutic efficacy by protecting the therapeutic agents from being physically, chemically, biologically 'degraded' before they reach the disease target site and being released at this site. For instance, siRNA has been encapsulated in a 70 nm cyclodextrin based polymer, conjugated with a protein as a targeting ligand and polyethylene glycol (PEG) polymer to promote stability.[15] Design strategies can also help

in escaping the biological barriers, have better control over drug release profile, increase absorption in tumours tissues, prevent therapeutic agents from interacting with normal cells and hence less systemic toxicities.[48–50] If these carriers are designed with the aim to treat CNS disorders, these features can also help the small drug molecules to cross the blood brain barrier and hence improve the therapeutic outcomes.

However, the design features necessary to make efficacious therapeutics might prove to have deleterious impacts on environmental biota and ecological health, when these medicines find their way into the environment. Furthermore, not all design features listed above can be met for development of a particular therapeutic. For example, PEG coated therapeutics, so-called 'stealth' nanoparticles are in advanced stages of clinical trials, however it has been found that PEG is not easily biodegradable in the human body (mentioned in ref. 5 and 51). At the same time, more targeted and in some cases reduced dosages might decrease the future environmental burden of conventional pharmaceuticals.

The context of existing pharmaceuticals and environmental risks

The primary focus of drug delivery research in nanomedicine has been to design delivery agents that would have the ability to cross the various biological barriers in the body and deliver therapeutic agents to the target site with the aim to increase therapeutic efficacy. The therapeutic agent might be conventional small molecule drugs which have found limited use in the clinic due to systemic toxic effects or poor solubility. This necessitates the review of the existing scientific literature on conventional pharmaceuticals in the environment. Concerns due to effects of pharmaceutical products (PPs)|| in the environment have been expressed[91,92] and this is now an active area of research. PPs from various therapeutic classes have been detected in the range of ng L^{-1} (and ng g^{-1}) to low µg L^{-1} (mg kg^{-1}) in different environment compartments, – sewage effluents,[93] surface waters,[94,95] receiving coastal waters,[96] estuaries,[97] sediments and soils,[98] landfill leachates,[99] and to a lower concentration and frequency in groundwater and drinking water sources.[100,101] In many cases (see Table 2) concentrations of PPs has shown to exceed the current PEC_{sw}** threshold limit value of 0.01 µg L^{-1} suggested by the EMA.[102] PPs have also been found in aquatic biota.[32,103,104] The widely detected pharmaceutical products in the environment belong to the therapeutic class of antibiotics, non-steroidal anti-inflammatory drugs, blood lipid lowering agents, sex hormones, central nervous system (CNS) disorder drugs and β-blockers (reviewed and summarized in ref. 105). A few examples of the occurrence of pharmaceuticals and their metabolites in different environmental compartments are presented in Table 2. Spatial, temporal and geographic variations (e.g., ref. 93, 106 and 107) have been shown

to occur in the concentrations and type of pharmaceutical products. Fluctuations in the concentrations of pharmaceutical products have also been shown in effluents and receiving water bodies during special episodes, e.g., of disease outbreaks.[108,109] In addition to monitoring campaigns, models such as SimpleTreat, LowFlow 2000-WQX, PhATE have been used to predict environmental concentrations in various compartments.[110,111]

Pharmaceuticals are metabolised and excreted out of the body either unchanged or in conjugated form (e.g. glucuronide, sulphates, glycinate conjugates) and hence the main sources for human pharmaceuticals and their metabolites in the environment have been identified as effluents of waste water treatment plants (WWTPs) from communities[112] hospitals[113] and pharmaceutical manufacturing facilities.[32] Approximately, 28% of the world's population in 2008 was not connected to sewage systems[114] and ca. 9% of the wastewater in EU countries is not treated or the waste water treatment systems do not have secondary treatment steps,[115] sewage systems are leaky[116] or contamination of storm water from waste water exists[117] thereby giving rise to the possibility of further environmental contamination. It has been established that the fate, removal and partitioning of these compounds are dependent on the design of the WWTP,[118] e.g., ibuprofen's removal efficiency was below 25% for a WWTP having primary treatment process compared with a removal efficiency of 90% in a WWTP having secondary treatment.[96] Furthermore, a few drugs have been shown to have negative removal percentages in the WWTPs, and it has been suggested that these negative removal percentages might be due to analytical instrumental errors, sampling variations, etc., but, it also gives credence to the hypothesis that the conjugated metabolites may undergo bio-transformation in the environment to form the parent drug (removal efficiencies in WWTPs has been reviewed in ref. 119). PPs can also undergo abiotic transformations in the environmental matrices including photo-transformation and hydrolysis and can be deactivated to ecologically benign molecules or form harmful transformation products. For instance, the photo-transformation of diazepam and its metabolites was recently studied[120] and the investigators concluded that diazepam (a widely prescribed antidepressant) would be transformed under conditions present in the environment. However, the photoproducts that were identified had chemical structures similar to identified endocrine disruptors (photolytic and oxidative transformation of drugs has been reviewed in ref. 121).

PPs like ibuprofen, acetaminophen, ciprofloxacin, ketoprofen, etc. have high removal efficiencies in WWTPs which have secondary treatment steps. However, studies have also established that certain PPs (e.g. fenofibrate and anthracyclines from the blood lipid regulator and anticancer therapeutic class respectively) sometimes get removed from the aqueous phase and get adsorbed to the sludge/solids.[122,123] This may be due to hydrophobicity, binding interactions with particles in soils, etc. and thereby contributing to a new exposure pathway when this nutrient rich sludge is used for agricultural purposes.

Pharmaceuticals are designed to affect biological receptors and hence it should not come as a surprise that they have stimulatory or inhibitory or dual effects on non-target organisms upon

---

|| The term 'pharmaceuticals products' (PPs) used in the text in this section includes prodrugs, pharmaceuticals, metabolites and transformation products. Unless otherwise mentioned, pharmaceuticals mean pharmaceuticals for human use.

** PEC_{sw} is Predicted Environmental Concentration in surface waters.

128 | Environ. Sci.: Processes Impacts, 2013, 15, 123–144

This journal is © The Royal Society of Chemistry 2013

Table 2 Measured environmental concentrations of select pharmaceuticals[a]

Category	Pharmaceutical product	Concentration	Environmental compartment	Region	Reference
Analgesics/NSAIDs	Acetaminophen	1.89 µg L^{-1} (max. conc.)	Groundwater	U.S.A. (California)	100
		0.08–13.8 µg L^{-1}	Treated effluents (5 STPs)	Spain	93
		1.4–5.9 µg L^{-1}	Untreated effluent from 2 hospitals	Italy	113
		0.012–0.058 µg L^{-1}	STP effluent	Italy	113
	Diclofenac	0.052–1.76 µg L^{-1}	Effluents (12 municipal WWTPs)	South Korea	142
		230 ng L^{-1} (median values)	WWTP effluents	Spain (Galicia)	143
		LOD = 2.95 µg L^{-1}	Effluents (3 WWTPs)	Ireland (Dublin)	144
		100–131 ng L^{-1}	STP effluent	Taiwan	96
		53.6 ng L^{-1} (max. conc.)	Coastal receiving area (6.6 km offshore)	Taiwan	96
	Mefenamic acid	LOD = 1.73 µg L^{-1}	Effluents (3 WWTPs)	Ireland (Dublin)	144
		44–392 ng L^{-1}	Effluents (5 STPs)	South Korea	145
	Ibuprofen	5 µg L^{-1} (max. mean conc.)	Effluents (5 STPs)	Spain	93
		552–1600 ng L^{-1}	STP effluent	Taiwan	96
		57.1 ng L^{-1} (max. conc.)	Coastal receiving area (6.6 km offshore)	Taiwan	96
		<MDL – 26.6 ng L^{-1}	Treated drinking water	U.S.A	101
		96.9–166 624 ng L^{-1}	Landfill leachate and inlet of leachate treatment	Norway	99
		120 ng L^{-1} (max. conc.)	River water	U.S.A.(Washington, D.C.)	146
Beta-blockers	Propranolol	1–24 ng L^{-1}	Estuary, harbour	Belgium	147
		3.18 ng L^{-1} (max. conc.)	Estuary	Portugal	107
		1.51–2.60 ng g^{-1}	Sediments of marshy areas	Valencia, Spain	98
		107.4 ± 36 µg kg^{-1}	Achieved biosolids (collected in year 2001) from 94 WWTPS	U.S.A.	148
	Atenolol	80–293 ng L^{-1}	Estuary, harbour	Belgium	147
		511 ng L^{-1} (median value)	WWTP effluents	Galicia, Spain	143
		1.1–15 µg L^{-1}	Effluents (5 STPs)	Spain	93
		261–5911 ng L^{-1}	Effluents (5 STPs)	South Korea	145
Blood lipid lowering agents	Fenofibrate	13.20–17.23 ng g^{-1}	Sediments of marshy areas	Valencia	98
		LOQ = 2.5 ng g^{-1}	Sludge (3 WWTPs)	Spain	122
	Gemfibrozil	0.15–1.24 µg L^{-1}	Effluent water	Spain (Valencia)	149
		0.08–19.4 µg L^{-1}	Effluent water	U.S.A. (Texas)	150
		0.11–6.86 µg L^{-1}	Groundwater below Land application site	U.S.A. (Texas)	150
Estrogens	EE2 (17α-ethinylestradiol)	2 ng L^{-1}	Effluents (11 STPs)	UK	151
	Levenogesterol	11 ng L^{-1}	Groundwater	France	152
Antibiotics	Ciprofloxacin	1.9 µg L^{-1} (max. conc.)	Effluents (5 STPs)	Spain	93
	Norfloxacin	256 ± 64 ng L^{-1}	Secondary effluent (1 STP)	China (Beijing)	153
		7.23 ± 0.22 mg kg^{-1}	Dewatered sludge (1 STP)	China (Beijing)	153
	Ofloxacin	8.95–12.03 ng g^{-1}	Sediments of marshy areas	Spain	98
		528 ± 89 ng L^{-1}	Secondary effluent (1 STP)	China (Beijing)	153
		2.8 µg L^{-1} (max. conc.)	Effluents (5 STPs)	Spain	93
		7.79 ± 0.55 mg kg^{-1}	Dewatered sludge (1 STP)	China (Beijing)	153
	Sulfamethoxazole	13–96 ng L^{-1}	Estuary, harbour	Belgium	147
		9.14–53.3 ng L^{-1}	Estuary	Portugal	107
		0.17 µg L^{-1} (max. conc.)	Groundwater	USA (California)	100
		0.047–0.397 µg L^{-1}	Effluents (12 municipal WWTP)	South Korea	142
		4.2–485 ng L^{-1}	Yangtze Estuary	China	97
	Lincomycin	1.06–45.7 µg L^{-1}	Effluents (12 municipal WWTP)	South Korea	142
		1437–21 278 ng L^{-1}	Effluents (5 STPs)	South Korea	145
Antineoplastics	Ifosfamide	4–10 647 ng L^{-1} (median, 151 ng L^{-1})	Hospital effluent (21 hospitals)	China	154
	Cyclophosphamide	6–2000 ng L^{-1} (median, 100 ng L^{-1})	Hospital effluent (21 hospitals)	China	154
	5-Fluorouracil	27 ng L^{-1} (max. conc.)	Hospital effluent	Switzerland	155
		0.09–4 µg L^{-1} (max. mean concentration = 0.8 µg L^{-1})	Monitoring point where hospital effluent was discharged to the sewage network	France	156
	Tamoxifen	102 ng L^{-1} (max. conc.) 26.5 ng L^{-1} (median conc.)	STP effluent	France	157

Table 2 (Contd.)

Category	Pharmaceutical product	Concentration	Environmental compartment	Region	Reference
Psychiatric drugs	Fluoxetine	11 ng L^{-1} (median conc.)	River	France	157
		120–127 ng L^{-1}	Yangtze Estuary	China	97
		8–44 ng L^{-1}	5 main rivers (Madrid)	Spain	94
	Norfluoxetine (metabolite of fluoxetine)	41.6 ± 25.1 µg kg^{-1}	Achieved biosolids (collected in year 2001) from 94 WWTPS	U.S.A	148
	Diazepam	Upto 80 ng L^{-1}	Effluents (5 STPs)	Spain	93
	Pipamperone	1.4–17.3 ng L^{-1}	Surface water	Belgium	158
	Sertraline	458 ± 168.3 µg kg^{-1}	Achieved biosolids (collected in year 2001) from 94 WWTPS	U.S.A	148
	Carbamazepine	4–321 ng L^{-1}	Estuary, harbour, sea	Belgium	147
		0.37–178 ng L^{-1}	Estuary	Portugal	107
		1.43–5.77 ng g^{-1}	Soils of marshy areas	Valencia, Spain	98
		1.81–6.85 ng g^{-1}	Sediments of marshy areas	Valencia, Spain	98
		2–272 ng L^{-1}	River (Lopan)	Ukraine	159
		0.208–21 µg L^{-1}	Effluents (12 municipal WWTPs)	South Korea	142
		3.6 µg L^{-1} (max. conc.)	Groundwater	U.K.	Cited in ref. 160
		0.42 µg L^{-1} (max. conc.)	Groundwater	U.S.A (California)	100
		Upto 6.8 ng L^{-1}	Treated drinking water	U.S.A	101
		161 ng L^{-1} (max. conc.)	Stormwater collection system (discharge outfalls)	Canada	117

^{a} Max. Conc.: Maximum Concentration; LOQ: Limit of Quantification; STP: Sewage Treatment Plant; WWTP: Waste Water Treatment Plant.

exposure to different concentrations especially when the targets and biochemical pathways are similar. A well-known example of this is the ER-receptor agonist and antagonist behaviour associated with naturally occurring and synthetic hormones (*e.g.* ethinylestradiol—the active ingredient in the oral contraceptives) which can result in endocrine disruption.[124] Sometimes non-target organisms, *e.g.* algae, cyanobacteria, which have non-related biochemical and metabolic pathways can also be effected upon exposure to pharmaceuticals.[125] Organisms might show limited toxicity in acute toxicity tests whereas higher toxicity in chronic tests for particular chemicals.[126] Mixture toxicity of PPs is of on-going concern as is their potential effects over many generations.[127] It has been observed that exposure to pharmaceutical products affects growth and behaviour of organisms, resulting in physical malformations, feminisation of males, changes in photosynthetic activity and metabolic processes. To date, very few ecotoxicity studies on pharmaceuticals have been conducted at environmentally relevant concentrations and hence there is inconclusive evidence to understand the true implications of their presence in the environment. See ref. 105 for a review of ecotoxicological studies of key pharmaceuticals. A key concern for nanomedicines is that their dual carrier and targeting functions may make existing PPs more bioavailable in the environment.

Early ecotoxicity studies reported toxicity effects at higher exposure concentrations and focused on growth inhibitory and reproductive effects. Recently, the shift in emphasis has been towards assessing impacts at low concentration and assessing the increased number of physiological biomarkers such as studying ROS production, transcription of genes, *etc.* For example, a decrease in nitrate reduction potential for groundwater bacterial communities was observed at 5 nM concentration of exposure to sulfamethoxazole[128] and changes in

behaviour of marine amphipods by exposure to fluoxetine (antidepressant, a selective serotonin reuptake inhibitor) at concentrations of 10 ng L^{-1} was reported.[129] A long term study in an experimental lake to assess the population level sustainability of the fathead minnow upon exposure to low levels (5–6 ng L^{-1}) of synthetic estrogens[130] has shown that there can be collapse of a population due to feminization of the males. Various publications have suggested the need for assessing mixture toxicity[131–133] because of the additive, cooperative and antagonistic effects of different class and compounds of pharmaceuticals.

Many knowledge gaps have been identified which makes the task of conducting a plausible environment risk assessment for pharmaceuticals challenging. These gaps in knowledge create large uncertainties and hence inconclusive results. Furthermore, analytical challenges, *e.g.*, non-extractable residues, interference by other contaminates in complex mixtures of sewage and hospital wastewater, and trace level of these compounds complicates the matter. We summarise here the few repeatedly mentioned knowledge gaps in the literature. Limited knowledge exists on:

• occurrence, fate and activity of metabolites and their transformation products in the environment, mode of action of pharmaceuticals, metabolites and excretion rates

• long-term exposure to low levels of pharmaceuticals, ecosystem level impact, mixture toxicity

• exposure and effects data on soil organisms and marine species, effects data on ionic and polar compounds, and

• bioconcentration factors and bioaccumulation.

Intensive research in the field of environmental occurrence, fate and consequences of drugs and transformation products took off in the 2000s since the first findings of occurrence of

pharmaceuticals and their metabolites in the late 1970s in sewage effluents in the US; however, their impacts on ecosystems are yet to be established with certainty. Only population level impact attributed with certainty to pharmaceuticals is the >95% decline in the population of the vultures in the Indian subcontinent due to extensive diclofenac use in veterinary medicines.[134] This case study is also widely cited as an example of unexpected routes of exposure and bioaccumulation in the published literature on the environmental impacts of pharmaceuticals. Many national and international collective and cross-sectoral efforts over the past few years (*e.g.*, ERApharm 2007,[135] KNAPPE 2008 (ref. 136) in the EU, MistraPharma of Sweden) have been able to bring the discussion to the forefront. Publicly accessible websites such as Pharmaceuticals in the environment, Information for Assessing Risks (http://www.chbr.noaa.gov/peiar/) and the Swedish medicine information portal (www.fass.se) provides information on medicines in the environment. More recently, key gaps in knowledge to help streamline research and efforts in this field have been identified.[137] Additionally, different approaches for prioritisation schemes for environment risk assessment for pharmaceuticals have been suggested, *e.g.* fish plasma model, LogP ranking, hazard based rankings, QSAR approach, and these ranking schemes have been conducted for a substantial number of pharmaceuticals.[138–140] In January this year, the European Commission put forward the proposal to amend the Water Framework Directives to include three pharmaceuticals in the list of priority substances in Annex X of the Directive.[141] The positive outcome of the above-mentioned initiatives are that regulatory steps are being taken, however, it also exemplifies the time lag between knowing, proving environmental impacts and development or amendment of regulatory guidelines.

This table gives a very small number of the different types of pharmaceuticals monitored in the environment. It is meant to provide to the reader an overview of measured concentrations from recently published studies (2009–2012), the different environmental compartments where PPs have been found, and in different regions of the world. For detailed reviews on occurrence, fate and ecotoxicity of pharmaceuticals and their metabolites the reader is suggested reviews elsewhere, *e.g.*, ref. 105, 121 and 161–163.

Possible sources, fate and effects of nanomaterials (NMs)†† in the environment

The continued thrust on nanotechnology as an innovation and economic driver‡‡[164] will result in development of a larger number of new and complex materials and will inevitably result in release of these materials in the workplace[165] and subsequently in the environment.[166] The possible entry routes of NMs in the

environment includes intentional (*e.g.*, for remediation purposes) or accidental releases, emissions from manufacturing facilities, abrasion and weathering of NMs containing products. The specific entry route into a particular environmental compartment will depend on the life cycle of the product and disposal method used, for example, washing of nanofunctionalised textiles will result in release of the NMs in the sewerage system and finally transportation to natural waters.[167] To the best of the knowledge of the authors, no actual field level environmental monitoring of NMs have been reported in the literature, though model environmental concentration estimates have been calculated and reported for selected NMs.[168]

As is the case of pharmaceuticals, NMs also give rise to transformation products in various environmental conditions. The type of transformation products that will form will depend on the nanoscale properties of the NMs and on the conditions of the environmental matrices, *e.g.*, magnetic iron nanoparticles aggregate at near neutral pH due to their near neutral zeta potential but at higher pH they are more dispersed.[169] The key transformation mechanisms can be aggregation (homo- and hetero-aggregation), dissolution, oxidation/reduction and adsorption.[170]

Under simulated situations it has been found that natural organic matter (NOM) like humic substances[171] and extracellular polymeric substances[172,173] influence fate and behaviour of NMs. Studies have shown that NOMs in the environment influence stability of the NM[174,175] and hence bioavailability and toxicity (reduction in toxicity shown in ref. 176, 177 and 178) although less effect of NOM on polymer coated NPs in some cases.[179] It has also been demonstrated that silver NPs in organic matter rich soil become more bioavailable after aging.[180] In addition to NOM, physico-chemical properties of the aqueous environmental compartment like pH, ionic strength, salinity, mineral content/hardness, *etc.* have also been shown to influence fate, behaviour and toxicity. For instance, it was shown that *E. coli* survived at pH 10 even at concentrations of iron oxide NPs (β_{eq} of 109 mg L^{-1} of FeO$_x$), however, *S. cerevisiae* (an eukaryote) had survival rates of less than 10%.[181] Hardness of water, at near neutral pH, can result in formation of aggregates and biouptake by filter feeders[182] or settling down and available to pelagic organisms or earthworms. High total organic carbon (TOC) and low ionic strength, conditions in freshwaters, can stabilise NMs and make it persistent and be available for filter feeders, fish and algae and low TOC and high ionic strength such as in sea water can aid in their rapid aggregation and settling.[183] Please see ref. 184–187 for further studies on possible fate, behaviour and effects of engineered nanomaterials in the environment.

The key factors influencing toxicity are composition, size, surface properties (both for the NM and the transformed products), sensitivity of the species and presence of other contaminants. For example, cationic branched polymer [polyethyleneimine (PEI)] coated AgNPs (10 nm) was shown to have increased toxicity to a Gram +ve bacterium, *bacillus* sp. when compared to citrate and PVP coated AgNPs.[188] Similarly, positively charged AuNPs of 2 nm size was reported to lyse *Bacillus subtilis*, but observed to have no effect on *E. coli*, a Gram −ve

---

†† In this review, nanomaterials (NMs) refer to all engineered or manufactured nanomaterials and do not cover incidental or natural nanomaterials. There is some understanding of manufactured NM fate and behaviour and nanomedicines, where there is little direct information, are a sub-set of NMs; therefore we focus on engineered NMs in this section to highlight potential nanomedicine behavior.

‡‡ See Janez Potočnik's, European Commissioner for Science & Research, statement at http://cordis.europa.eu/nanotechnology/

Fig. 1 A conceptual schematic showing likely sources and transport of nanomedicine into the environment. Nanomedicines and transformed products may be released into the water through the excretory routes, washing off from skin, from manufacturing facilities, spillages and disposal of product. They can be released in the atmosphere from nasal inhalers. Incineration of composite medical products and abrasion and weathering in landfills may lead to release into the atmosphere.

bacterium.[189] Bioaccumulation and trophic transfer of NMs can also happen.[190,191] Many investigators have shown biofilms to be an effective sink for NMs[190,192,193] and aquatic organisms like filter feeders to uptake and biotransform suspended and dispersed NMs present in the aquatic matrix.[194,195] Furthermore, exposure of organisms to NMs would be dependent on the presence of other environmental contaminants, mode of action of the chemical and the differences in physiology of species. Phenanthrene adsorbed on n-C60 was shown to be more bioavailable to algae and daphnids, but was found to be more toxic to algae[196] and the investigators suggested the difference in physiology to be the reason for this observation. Whereas, n-C60 fullerenes was shown to sequester the synthetic hormone, 17-α ethinylestradiol (EE2) hence reducing its bioavailability.[197] Similarly, it was demonstrated that mixed iron oxide NMs in organic matter rich environment (humic acid >20 mg L^{-1}), low salinity (tap water and deionised water), and in a pH range of 5–7 could adsorb the antibiotic chlorotetracycline.[198] Interactions between hydrophobic NMs and pharmaceutical products can sequester PPs from the environment hence reduce or increase their bioavailability in a given time frame.

Possible sources, fate and effects in the environment of nanomedicines

There is insufficient knowledge regarding possible amounts and entry routes of nanomedicine products in the environment, however it should not deter one from making estimates of likely routes of entry, based on knowledge of environmental release and transport of pharmaceuticals. Fig. 1 is a conceptual model

of likely release and exposure pathways of nanomedicine and a key research issue is to quantify the concentrations and fluxes within this conceptual model. There are different entry routes for various medical NMs in the environment. In case of therapeutic applications, the obvious route is the renal and the hepatobiliary§§ routes of excretion to domestic sewage and then subsequently to waste water treatment plants and to receiving water bodies and land (with the caveat mentioned earlier that a large percentage of waste water even in the EU goes untreated). Other possible routes are likely to be NM release into the air from inhalers, disposal of unused medicine at hospitals, R&D labs, and clinical research facilities by casual and ill trained staff, NM release during manufacturing, transport and accidental spills, and from the incinerators. Due to high specific surface areas NMs might get adsorbed on to waste solids of the combustion chamber in an incinerator or be present in the off-gas.[199] However, complete removal of NPs below 100 nm from the off gas of the incinerator might not happen, even after state-of-the art effluent gas treatment processes.[200]

In case of medical devices, improper disposal of the devices at end of their life, especially disposable of *in vitro* diagnostic products is likely to release NMs into the environment. Although we know quantitatively very little at the moment, *a priori* it might be expected that certain pathways are likely to be

---

§§ Bile formation in the liver helps to bio-transform the drug and helps in drug metabolism. Excretion is primarily in the form of faeces. Other routes of drug excretion are *via* saliva, breast milk, intestinal exosorption (see ref. 201).

of major importance, including: (1) waste water and storm water to waste water and sludge and then to freshwater and soil; (2) treated flue gas from incineration to atmosphere and then to water and soil and (3) landfill to groundwater and soil and then to surface water.

Biotransformation and excretion

Ingested and injected PPs are amenable to biotransformation in the body due to the action of various enzymes and are excreted primarily with urine and/or faeces.[201] Studies have been performed to find out the clearance mechanisms of NMs with prospective use in medicine. Biodistribution studies with gold nanoparticles have been conducted by different investigators and it has been found that the clearance pathway is dependent on size, surface coating and charge of the particle. Lipka *et al.*[202] showed that 10 kDa PEG coated 5 nm AuNPs followed the hepato-biliary clearance route, whereas another study[203] showed uncoated 20 nm AuNPs to be primarily recovered in the urine. A recent study showed that hepato-biliary clearance was inversely related to negatively charged AuNPs of different sizes (1.4, 2.8, 5, 18, 80, 200 nm). The investigators concluded that the small sized negatively charged AuNPs were excreted out *via* the hepato-biliary excretion pathway because of "dynamic protein binding and exchange which are major mechanisms determining the AuNP accumulation in the various organs and tissues…".[204] By extension, there might be differences in biodistribution profile of encapsulated and free drug. A study showed that urinary excretion of the unaltered drug when encapsulated in poly-epsilon-caprolactone (a widely researched polymer for medical applications) nanocarriers increased by ~15% in comparison to the administration of non-encapsulated drug,[205] hence would result in more discharge to the environment unless dosages are altered. Biological fate of a model PEG–protein was studied and it was found that 46.5% of PEG of the administered dose was excreted out of the urine over a period of few days. The same study also reported that intact PEGylated model protein was excreted out in the first few days post administration of the model protein.[206]

In many cases, nanoformulations help to reduce systemic toxicities especially for anticancer drugs. For example, nab-paclitaxel, a nanomedicine in the market, is a formulation of paclitaxel (empirical formula: $C_{47}H_{51}NO_{14}$, a plant alkaloid) bound to albumin nanoparticles with mean particle size 130 nm has been shown to have better therapeutic efficacy than conventional paclitaxel (Taxol®) for breast cancer. The dosage of this new formulation is 260 mg m^{-2} of body surface area every 3 weeks (Taxol's prescribed dosage ranges from 135 mg m^{-2} to 175 mg m^{-2} of body surface area every 3 weeks),[207,208] showing the possibility of higher doses that can be achieved through nanoformulation. Traditional chemotherapeutics are highly hydrophobic drugs, and hence are generally assumed to be adsorbed on to the sludge of STP[123] and then mainly incinerated or spread on agricultural soils (Switzerland and UK, respectively). The possibility of administering increased dosages and changed excretion profiles due to the new nanoformulations will likely increase the environmental concentration of these highly cytotoxic

pharmaceutical products. The above examples indicate the likely problem areas; however, the authors acknowledge the fact that more targeted medicines, customised for small populations (personalised medicines) and possibility of reduction in premedication amounts might result in a more favourable benefit-risk balance when all aspects are taken into consideration.

Fate and behaviour

Polymer coating on NMs will affect the fate and behaviour of NMs in waste water treatment plants. Tween 20 coated silica oxide nanoparticles (~56 nm) were shown to remain in the sludge, whereas uncoated silica oxide NP did not flocculate and remained in the effluent.[209] Biofilms can act as potential 'sinks' for NMs either in the secondary treatment stage of a sewage treatment plants or in fresh water ecosystems. Sometimes, the polyethylene glycol (PEG) coating on NM can integrate itself with the protein component of the biofilm and change the roughness co-efficient of the biofilm but shielding the toxic effects of the core particle.[192] The size can also have an influence of changing the morphological properties of a biofilm. Stojak *et al.* reported an increase in roughness coefficient and significant decrease in plankton biomass in a *L. pneumophila* mature biofilm after 2 days of exposure to citrate capped of Au nanoparticles of sizes 4 and 18 nm.[193] However, no change was observed in the biofilm exposed to 50 nm gold NPs. Furthermore, it was observed that the 4 nm and 18 nm AuNPs got adsorbed onto the exopolysaccharides of bacterial cell wall and also got entrapped in the bacterial cell.[193] Polymers may be utilised as carbon/energy sources. It was recently demonstrated that PEG coated NM could be degraded by bacteria from an urban stream. However, the degradation rate and aggregation depended on the available chain end groups of the two different types of polymer coated NMs studied.[210] Polymer (poly ethylene glycol-*b*-ε-caprolactone) coated nanoparticles were found to irreversibly adsorb onto cellulosic surface and the adsorption mechanism was found to be size dependant. The investigators hypothesised that adsorption could be due to interdigitation and entanglement of the nanoparticles with the D-glucose chains of cellulose.[211]

Biouptake and effects

Monodispersed, stable and targeted nanomaterials are important for medical applications, *e.g.*, monodispersed iron oxide nanoparticles[7,212] to fully exploit their novel properties, increase shelf life and to influence physiological responses with increased effectiveness. These same design requirements may dictate the fate and risk of the nanomaterial in the environment by not only arresting growth and reproduction, but also interfering with metabolic processes and hence in turn impacting key ecosystem services. However, to a certain extent organisms might be able to tolerate the exposure of nanomedicines although this is poorly quantified.

Nanoparticles are coated with organic polymer coatings to escape the mononuclear phagocytic system in the body ('stealth' properties) or to especially target cells. There are

Table 3 Select ecological studies of toxicity effects, uptake and bioaccumulation for NMs and nanocarriers with likely use in nanomedicine

The 'nano' component in nanomedicine	Short description of select ecological studies of toxicity effects, uptake and bioaccumulation for NMs and nanocarriers with likely use in nanomedicine	References
Polyethyleneimine (PEI) polymer	For tadpole larva, *Xenopus laevis*, both PEI and PEI:DNA (polyplex) showed teratogenic effects at concentrations 0.1 μg L^{-1}. PEI also showed higher toxicity for the algae *Pseudokirchneriella subcapitata*; $EC_{10} = 40.8$ μg L^{-1}. The polyplex was found to be less toxic to the algae than the free polymer	213
Dendrimers	Commercially available amine terminated G4 dendrimer showed sublethal toxicity in zebrafish embryos at 0.2 μM concentrations, whereas COOH terminated G3.5 dendrimers did not exhibit toxicity even at concentrations of 200 μM. Dose and time dependant mortality was observed for amine terminated G4 dendrimer, 100% mortality at dose 20 μM in 24 h post fertilisation	214
	Green algae *Chlamydomonas reinhardtii* exposed to commercially available amine terminated G2 (2.6 nm), G4 (4.4 nm), G5 (5.7 nm) poly(amidoamine) PAMAM dendrimers showed decreased cell viability at 2.5 mg L^{-1} (median IC$_{50}$ as per dendrimers generation: G2, G4, G5, – 2 mg L^{-1}, 3 mg L^{-1}, 5 mg L^{-1}). O$_2$ evolution from photosynthesis significantly increased at concentrations 1 mg L^{-1} and 2.5 mg L^{-1} for G2 and G4 dendrimer (increase in PSII reaction centres and e$^-$ transport). Exposure concentrations: 0.3, 1, 2.5 and 10 mg L^{-1}. Exposure duration: 72 h	215
	Commercially available G4 cationic PAMAM dendrimers with diaminobutane core at 15 nM, 25 nM and 35 nM concentrations resulted in a linear increase in ROS level and photosynthetic oxygen level in the algae, *C. reinhardtii*. Also, most of the transcripts encoding proteins involved in photosynthesis and antioxidant genes were down regulated except for the gene which encodes light-harvesting polypeptide for PSII (this was upregulated). Measured size range: ~90 nm in MQ water. Exposure duration: 6, 24 h	216
	A dose-effect study of amine terminated G4 and G1 PAMAM dendrimers with ethylenediamine core was conducted for *P. subcapitata*. The amine-terminated G4 dendrimer was found to be comparatively more toxic than the amine terminated G1 dendrimer. The negatively charged hydroxyl terminated G4 dendrimer had least toxicity	217
SPIONS and USPIOs (<25 nm core)	Pumpkin plants (*Cucurbita maxima*), when grown hydroponically could translocate and accumulate coated magnetite (Fe_3O_4) nanoparticles (20 nm size). Strong magnetisation signals were observed in the leaves. Exposure concentration: 0.5 g L^{-1}; exposure period: ~20 days. Also, when pumpkin plants were grown in soil, no magnetisation signal was noticed in the plants but when grown in sand, the pumpkin plants accumulated the iron nanoparticles. Lima bean plants didn't accumulate Fe_3O_4 nanoparticles	218
	Higher activity of the oxidative stress enzyme catalase was reported for PVP coated magnetite (Fe_3O_4) nanoparticles (25 nm) and bulk iron oxide NPs in the shoots of both rye grass and pumpkin plants and roots of rye grass plants. Exposure concentrations: 30 mg L^{-1}, 100 mg L^{-1} of nano-(Fe_3O_4) and 30 mg L^{-1} and 100 mg L^{-1} of Fe_3O_4 bulk. Exposure duration was 18 days. Lipid peroxidation was also reported. No magnetism was observed in the shoots of both the plants, indicating, that the iron NPs were not translocated. The oxidative stress enzyme superoxide dismutase activity was found to be higher in the roots of both the plants for iron bulk and nanoparticles at 30 mg L^{-1} concentration	219
	In the presence of sublethal concentrations of As(v) (to rule out the probability that environmental arsenic is causing the toxicity), commercial nano-Fe_2O_3 (20–40 nm) was shown to have increased toxic effect on *C. Dubia*. It was established nano-Fe_2O_3 and As(v) caused the toxic effect in a synergistic mode (nano-Fe_2O_3 alone didn't exhibit mortality under the concentrations used in the study). It was found that 48 hour mortality was dose dependant but 24 h mortality was not. At 20 mg L^{-1} of nano-Fe_2O_3, the 48 hour mortality increased from 30% to 70% and then the mortality rate remained nearly constant for higher exposure doses. Depuridation (upto 75%) occurred after an hour for solutions having algal feed. It was observed that maximum bioaccumulation occurred at neutral pH. Exposure concentration: 1, 5, 10, 20, 50 mg L^{-1}	220
Gold nanoparticles (different sizes for different medical applications; general size range 5–30 nm)	Decrease in colony forming units of soil microbial community after 15 days of exposure to commercial available AuNPs. Higher shoot/root ratio of lettuce exposed to AuNPs observed indicating that AuNPs acted as a growth promoter. Concentration: 0.013% w/w in soil. Exposure time in soil: 15 days	221
	Size selective uptake of citrate capped AuNP by tobacco plants. 3.5 nm AuNPs were found in the leaves of the plants and the 18 nm AuNPs remained agglomerated/aggregated at the root surface. Necrotic lesions in leaves and death of plants occurred after 30 days of exposure. Concentration: 3.5 nm – 48 ppm; 18 nm – 76 ppm. Exposure duration: 3 to 30 days	222
	Mean 'Au' concentrations in tobacco plants were found to be between 2.2 mg kg^{-1} to 53.5 mg kg^{-1} when hydroponically exposed to tannate and citrate coated 10, 30, 50 nm of AuNPs. In contrast, wheat plants when exposed to the same exposure concentrations didn't show any uptake. However, it was found that aggregation of AuNPs occurred more in the wheat than the tobacco plant suspensions. Exposure concentration: 30 mg L^{-1}. Exposure time: 7 days for tobacco and 3 days for wheat	223
	No obvious toxic effects of cucumber and lettuce seeds could be seen when exposed to AuNPs of mean size 10 nm at 2.4×10^{12} NP mL^{-1} concentration	224
	Polyvinyl alcohol (PVA) capped Au NPs [size range: 15–35 nm (spherical shape)]. Exposure concentrations: 10, 25, 50, 75, and 100 μg mL^{-1} were used to study their impact on embryos of zebra fish. The embryos developed normally (similar to the controls) – eyes, tail, brain and otoliths. No change in blood flow or cardiovascular development was observed. Detectable AuNP accumulation was observed in the body of treated embryos (25 and 50 μg mL^{-1})	225

Table 3 (Contd.)

The 'nano' component in nanomedicine	Short description of select ecological studies of toxicity effects, uptake and bioaccumulation for NMs and nanocarriers with likely use in nanomedicine	References
	Zebrafish exposed to citrate stabilised gold nanoparticles (12 and 50) nm through feed. Daily dose 90 ng and 106 ng for 12 and 50 nm Au NPs. Exposure duration 36 days. Daily dose: 36 and 42 ng for 12 and 50 nm AuNPs respectively. Exposure duration: 60 days. AuNPs were found in brain, liver and skeletal muscles with highest concentration of 12 nm AuNPs in the brain. Up-regulation of DNA repair genes, increase in mutation and mitochondrial impairment was observed and was more for the 60 days exposure duration	226
	(1) Feed containing citrate capped 15 nm AuNPs fed to *D. melanogaster*. Max. dose: 12 µg per g per day. Life span and fertility was negatively affected. Reproductive performance decreased with exposure to increasing AuNP doses (from 1.9 pmol L^{-1} to 380 pmol L^{-1}) during embryonic and larval development. Overexpression of heat shock protein occurred reflective of ER stress and DNA fragmentation in the gastrointestinal tissue was observed	227
	(2) Feed containing citrate capped 15 nm AuNPs fed to *D. melanogaster*. Max. dose: 3 µg per g per day. Mutagenic effects were observed and aberrant phenotypes were observed in subsequent (F1 and F2) generations	228
	Oxidative stress observed in *Mytilus edulis*, a marine bivalve mollusc, when exposed to 750 ppb AuNPs (5.3 nm size), for 24 h. The study also showed that larger size Au-NPs resulted in lower oxidative stress in the animal. It was found that the AuNPs accumulated mainly in the digestive gland	229
	Filter-feeding bivalve *Corbicula fluminea* (1–2 years of age) exposed to Bovine Serum Albumin (BSA) coated AuNPs of sizes 7.8 nm, 15 and 46 nm. Exposure concentration: 2 mg L^{-1}. Total exposure time: 180 h • Efficiency of removal of AuNPs from solution due to filtration by the bivalves was size dependant and removal efficiency increased with particle size • When the bivalves were exposed to varying concentrations (2 mg L^{-1}, 4 g L^{-1} and 8 mg L^{-1}) of 46 nm size BSA–Au NPs, it showed that removal efficiencies from solution to be positively related with concentration of BSA–AuNPs solution • The AuNPs were evidenced in the digestive gland and regions of the digestive tract and mass concentration inside the body of the clam was more for the 15 nm of BSA–AuNP exposed bivalves • The bivalves exposed to 7.8 nm AuNPs particles, didn't efficiently excrete it during the experimental period and it was found that AuNPs concentrations remained elevated in these bivalves. 15 and 46 nm BSA–AuNP exposed bivalves excreted out the AuNPs more efficiently	194
	Evaluation of toxigenomic response of *Caenorhabditis elegans* (soil nematode) exposed to 4 nm citrate capped AuNPs (LC$_{10}$ = 5.9 mg L^{-1} at 24 h and same concentration used for the genetic response analysis to AuNPs). Observations reported are as follows • Upregulation of genes related to clathrin-mediated endocytotic pathway • Upregulation of Ca+ signalling and amyloid processing pathway (protein unfolding and denaturation) • Upregulation of heat shock protein genes (reflective of ER stress)	230
Silicon oxide NPs	Commercially available silica NPs (50% were below size 100 nm, 40% were between 100 and 200 nm) at concentrations of 0.825 mg mL^{-1} was shown to affect the endoplasmic reticulum function leading to ER stress response, in a fish fibroblasts cell line	231
	Commercially available silica NPs of size 10–20 nm diameter were found to decrease growth rate of *S. obliquus* (a fresh water green algae) as a function of concentration (50, 100, 150 mg L^{-1}) and time (48, 72, 96 h). Contents of chlorophyll-a and b decreased by 86.4% and 94.8% as compared to the control group, but the amount of carotenoids didn't decrease. Exposure duration: 96 h of exposure at 50 mg mL^{-1}	232
	SiO$_2$ NPs (commercially available) of 12.5 and 27 nm shown to be toxic to *P. subcapitata* (green algae) EC$_{20}$ was found to be 20 ± 5 mg L^{-1} and 28.8 ± 3.2 mg L^{-1} for 12.5 nm and 27 nm. Adsorption to the cell wall was seen but no cellular uptake was observed by the investigators. Exposure duration: 72 h	233

limited numbers of ecotoxicity studies which have been conducted with polymers used in medical applications, of the few that we are aware of, most of the studies have been done on dendrimers.

Dendrimer toxicity has been shown to increase with increase in the generation of cationic dendrimers for various model organisms (*D. magna*, *V. fischeri*, *P. subcapitata*, *T. platyurus*). Table 3 gives a summary of selected ecotoxicity studies which can be linked with NMs used in medical applications. The environmental sources, fate and effects of AgNPs have been widely reported in the scientific literature and therefore this

table does not cover ecotoxicity studies of AgNPs. Readers are referred elsewhere for a review on fate and effects of AgNPs in the environment.[184]

Regulatory framework for medicines and medical devices in the EU

Regulations for pharmaceuticals for human use

Extensive studies for assessing toxicity are conducted after identification of a promising new entity that has a therapeutic potential. A battery of tests and assays are performed to

Fig. 2 General stages of nanomedicine development and the key points of interaction between regulatory agencies and nanomedicine developers. Good Laboratory Practices, Good Manufacturing Practices, Good Clinical Practices are the quality and ethical guidelines followed by pharmaceutical companies and researchers and monitored by regulators. Rapid advancement in technology and science and need for innovation to be an economic driver, regulatory agencies are present in earlier stages of product development.

understand whether there are risks for human carcinogenicity, genotoxicity, reproductive and development toxicity, immuno-toxicity, *etc.*). Pharmacodynamics and pharmacokinetics studies are conducted in small animal models to assess the distribution of the drug, the mode of action and physiological effects, metabolism and excretion. Data from these studies is required to be submitted to the relevant medical regulatory agency before enrolling human subjects to establish the safety and efficacy (Phase I to Phase III clinical trial) of the new drug. The preclinical and the clinical trial data form the basis of the marketing authorisation application (MAA) in the EU and member states. Applications for therapeutics for cancer, neurodegenerative diseases, HIV/AIDS and immune dysfunctions, and viral diseases are submitted to the centralised medical regulatory agency in the EU, the European Medicines Agency. A few other therapeutics which go through the centralised procedure include officially designated 'orphan'¶¶ medicines, biotechnology based therapeutics, tissue engineering products. Marketing surveillance ('pharmacovigilance') of the medicine post authorisation are other regulatory steps

which should help to monitor the therapeutic agent's safety. Fig. 2 is a simplified depiction of the medicine innovation pathway, key checkpoints with regard to regulatory agency involvement and the underlying guidelines for ethics and safety during innovation. The decision for approving a medicine is based on the careful evaluation of the benefit-risk assessment of a particular therapeutic for the target group of patients.

Medical devices legislation

The regulatory context with regard to medical devices in the EU is substantially different to that of medicines for human use. Medical device and medicine regulatory pathway have distinct and clearly demarcated regulatory process. The medical device directives are implemented at EU member state level with no overarching body at the EU level. There are three different regulations to capture all the different types of devices used in the medical industry – the Medical Devices Directive, Active Implantable Medical Device Directive, and In Vitro Diagnostic Medical Device Directive. Combination products *i.e.* integration of a medical device and medicine, spurred by nanotechnology, has blurred the distinction between the two distinct regulatory pathways and need for revisions in the current legal framework has been voiced in the public consultation process, a part of the undergoing process of revision (2008-onwards) of the medical devices directives. Also, few member state regulators (*e.g.* UK, Sweden) have taken required steps towards addressing the issue.

Medical devices are classified according to their perceived level of risk – Class I representing the lowest level of expected/

¶¶ To qualify for *orphan designation*, a medicine must meet one of these criteria (as defined by the EMA, ref. 234): (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than 5 in 10 000 people in the EU at the time of submission of the designation application; (2) it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and without incentives it is unlikely that the revenue after marketing of the medicinal product would cover the investment in its development.

136 | *Environ. Sci.: Processes Impacts*, 2013, **15**, 123–144

This journal is © The Royal Society of Chemistry 2013

Fig. 3 Key requirements in the tiered environment risk assessment process for medicines for human use. For anti-microbials, if the PNEC:PEC$_{sw}$ is less than 0.1, need for extended environmental fate and effect studies becomes mandatory which includes soil and sediment compartments and terrestrial organisms. PNEC: Predicted No Effect Concentration; PEC: Predicted Environmental Concentration; K_{oc}: adsorption co-efficient; K_{ow}: octanol–water co-efficient; PEC$_{sw}$: PEC surface water; PEC$_{gw}$: PEC ground water.

perceived risk and Class III representing the highest level of risk. The degree of risk assigned then determines the level and type of evidence required for award of CE (*Conformité Européenne*) mark. Clinical data is required for awarding a CE mark for Class III medical devices but are not mandatory; literature analysis showing clinical investigations and experience related to similar devices and appropriate justification can be used for submission of application for approval.[235] Tests to identify human toxicological risks from materials used in medical device components, (*e.g.* polymers) need to be performed. However, no environmental risk assessment of medical devices is required. Unfortunately, the medical devices directives do not cover the entire life cycle of the product and their disposal in the EU was according to the WEEE Directive (Waste Electronic and Electrical Equipment Directive 2002/96/EC) which did not mandate recycling and recovery percentages for medical devices giving rise to the concern that similar environmental and occupational health problems as electronic waste [236] may occur for the use of cost-effective mass produced nano-enabled *in vitro* diagnostic tools. However, the recently revised WEEE Directive has mandated recovery and recycling targets for certain medical devices.[237]

Current regulatory context (human medicines) related to environmental safeguard

The European Medicines Agency's Guideline on Environmental Risk Assessment (ERA) of pharmaceuticals[102] follows a tiered

assessment approach: Phase I and Phase II (Tier A and Tier B). Fig. 3 gives a concise schematic explanation of the approach. An ERA needs to be provided with every new marketing authorisation application (MAA) for a pharmaceutical; however, granting of market authorisation is independent of environment impact.

There are two initial pre-screening steps – (a) if the predicted environment concentration of the pharmaceutical exceeds the threshold value of 0.01 μg L^{-1} (0.01 ppb), then it triggers the need for conducting few acute ecotoxicity tests on regulatory species to calculate the Predicted No Effect Concentration (PNEC) (b) if the octanol–water partition co-efficient (log K_{ow}) is greater than 4.5, persistence, bioaccumulation and toxicity (PBT) assessment tests need to be conducted by following ECHA's guidance on chemical safety assessment. Firstly, the questions arise, how is the PEC calculated for nanomedicines? Apart from concerns which are similar to all NMs, should it to be based on the drug, the nanocarrier or on the nanocarrier–drug conjugate? How would the PEC be derived for more complex nanomedicines? As with all NMs, nanomedicines may present unique concerns and the applicability of such ERAs have not been fully demonstrated.

Secondly, it is well established that log K_{ow} has deficiencies as a surrogate for determining mobility and partitioning of PPs or for application to NMs.[238] For example, the antidepressant carbamazepine was found in fish tissues from effluent dominated streams though the drug has a log K_{ow} of 2.67. Similarly, ciprofloxacin, an antibiotic, sorbs well onto active sludge or

sediments,[153,239] despite a log K_{ow} of -1.74 (cited in ref. 240) and it was found to be persistent.[241] It has been widely debated that log K_{ow} for acidic and basic drugs is misleading, because the coefficient is dependent on solution pH, ionic strength, NOM and other factors. In the case of NMs, the inadequacy of the test protocol to determine log K_{ow} has been discussed.[238] A study performed on different generations of dendrimers showed that for dendrimers with terminal NH_2 group, the log K_{ow} of the polymer was negative for G1–G5 PAMAM dendrimers and G6–NH_2 and G8–NH_2 dendrimers partitioned at the octanol–water interface.[242] The negative log K_{ow} indicates that under the current ERA guidelines, there will not be any need to conduct a TIER 1 risk assessment. Similarly, PEG has negative log K_{ow} and it doesn't change much with the chain length, furthermore, it is not easily biodegradable.

Although the action limit 0.01 µg L^{-1} is very low, it is based on *acute* rather than chronic toxicity tests and it has been widely discussed both for pharmaceuticals and nanomaterials, that chronic and sub-lethal toxicity end points are important to assess the environmental risks of the product and that the link between chronic and acute toxicity is not well established for NMs. Furthermore, the test protocols suggested in the ERA Guidelines for human pharmaceuticals for conducting the physical–chemical fate and effects studies is based on OECD test guidelines for chemicals. The recommended study types include adsorption–desorption using a batch equilibrium method, a ready biodegradability test, aerobic and anaerobic transformation in aquatic test, algae growth inhibition, daphnia reproduction test, *etc.* The drawbacks and the need for adaptability of the current OECD tests and protocols, originally meant for chemicals, with respect to NMs have been discussed and reviewed.[243,244] Key issues are the influence of the test medium conditions on the NMs,[245–247] the need to include benthic and filter feeding organisms as test species, the necessity of investigating chronic effects and finding novel toxicity end points, the need for extensive *in situ* physico-chemical characterisation, the limited applicability of the persistence and bioaccumulation tests. The applicability of testing to nanomedicines will include the same issues and perhaps other specific ones including role of the nanocarrier in increased uptake.

Knowledge gaps and uncertainties and conclusion

Despite much progress in recent years, knowledge and data gap exists for pharmaceuticals, including their metabolic products and excretion rate, and their environmental fate and behaviour, removal efficiencies in sewage treatment plants, chronic toxicity data and bioaccumulation.[136] In nanotoxicology and nano-ecotoxicology, the key gaps include environmental concentrations, environmental fate and behaviour, dynamic changes in physical and chemical properties both *in vitro* and *in vivo*, applicability of exposure assays, dose metrics for exposure assessment, biouptake and toxicity mechanisms and chronic/acute toxicity relationships.[185–187,243] In nanomedicine, all these gaps in knowledge and data apply, along with others such

potential discharges to the environment and medium term growth in applications. Given the significant potential benefits of nanomedicine such as potential for dose reduction, it is imperative to further understand any potential environmental risks to allow the long term safety, sustainability and development of the industry. However, further understanding of the impacts of nanomedicine in the environment can be provided by use of data from the pharmaceuticals, environmental and nanoscience fields. In addition, sophisticated models and techniques are available which can be applied and adapted to understanding the environmental implications of nano-medicine. Although caution needs to be exercised as there will be discipline-dependent differences, such methods, data and models provide a solid platform for future more specific studies which are urgently needed.

Acknowledgements

References

1 G. Wang and J. Guan, *J. Nanopart. Res.*, 2012, **14**, 1–14.

2 M. L. Grieneisen, *Nat. Nanotechnol.*, 2010, **5**, 825.

3 A. E. Nel, L. Madler, D. Velegol, T. Xia, E. M. V. Hoek, P. Somasundaran, F. Klaessig, V. Castranova and M. Thompson, *Nat. Mater.*, 2009, **8**, 543–557.

4 S. Mitragotri and J. Lahann, *Nat. Mater.*, 2009, **8**, 15–23.

5 R. Duncan and R. Gaspar, *Mol. Pharmaceutics*, 2011, **8**, 2101–2141.

6 D. P. Cormode, T. Skajaa, Z. A. Fayad and W. J. M. Mulder, *Arterioscler., Thromb., Vasc. Biol.*, 2009, **29**, 992–1000.

7 D. Ho, X. Sun and S. Sun, *Acc. Chem. Res.*, 2011, **44**, 875–882.

8 M. Swierczewska, G. Liu, S. Lee and X. Chen, *Chem. Soc. Rev.*, 2012, **41**, 2641–2655.

9 M. J. Hawkins, P. Soon-Shiong and N. Desai, *Adv. Drug Delivery Rev.*, 2008, **60**, 876–885.

10 D. Rayson, T. M. Suter, C. Jackisch, S. van der Vegt, B. Bermejo, J. van den Bosch, G. L. Vivanco, A. M. van Gent, H. Wildiers, A. Torres, L. Provencher, M. Temizkan, J. Chirgwin, J. L. Canon, G. Ferrandina, S. Srinivasan, L. Zhang and D. J. Richel, *Ann. Oncol.*, 2012, **23**, 1780–1788.

11 U.S. Environment Protection Agency, *Flexographic Ink Options: A Cleaner Technologies Substitutes Assessment*, http://www.epa.gov/dfe/pubs/flexo/ctsa/frontv1-apr02.pdf, accessed 13 October 2012.

12 T. M. Allen and C. Hansen, *Biochim. Biophys. Acta, Biomembr.*, 1991, **1068**, 133–141.

13 W. J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins and J. O'Shaughnessy, *J. Clin. Oncol.*, 2005, **23**, 7794–7803.

138 | *Environ. Sci.: Processes Impacts*, 2013, **15**, 123–144

This journal is © The Royal Society of Chemistry 2013

14 S. Svenson, M. Wolfgang, J. Hwang, J. Ryan and S. Eliasof, *J. Controlled Release*, 2011, **153**, 49–55.

15 M. E. Davis, J. E. Zuckerman, C. H. J. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel and A. Ribas, *Nature*, 2010, **464**, 1067–1070.

16 Y. Matsumura, *Adv. Drug Delivery Rev.*, 2008, **60**, 899–914.

17 O. Lőrincz, E. R. Tőke, E. Somogyi, F. Horkay, P. L. Chandran, J. F. Douglas, J. Szebeni and J. Lisziewicz, *Nanomed.: Nanotechnol., Biol. Med.*, 2012, **8**, 497–506.

18 M. Perfezou, A. Turner and A. Merkoci, *Chem. Soc. Rev.*, 2012, **41**, 2606–2622.

19 C. S. Thaxton, R. Elghanian, A. D. Thomas, S. I. Stoeva, J.-S. Lee, N. D. Smith, A. J. Schaeffer, H. Klocker, W. Horninger, G. Bartsch and C. A. Mirkin, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 18437–18442.

20 G. Peng, U. Tisch, O. Adams, M. Hakim, N. Shehada, Y. Y. Broza, S. Billan, R. Abdah-Bortnyak, A. Kuten and H. Haick, *Nat. Nanotechnol.*, 2009, **4**, 669–673.

21 L. M. Manus, D. J. Mastarone, E. A. Waters, X. Q. Zhang, E. A. Schultz-Sikma, K. W. MacRenaris, D. Ho and T. J. Meade, *Nano Lett.*, 2010, **10**, 484–489.

22 M. L. Etheridge, S. A. Campbell, A. G. Erdman, C. L. Haynes, S. M. Wolf and J. McCullough, *Nanomed.: Nanotechnol., Biol. Med.*, 2012, DOI: 10.1016/j.nano.2012.05.013.

23 BCC Research, *Nanotechnology in Medical Applications: The Global Market*, 2010, http://www.bccresearch.com/report/HLC069A.html, accessed 22 December 2010.

24 BCC Research, *Nanotechnology in Medical Applications: The Global Market*, 2012, http://www.bccresearch.com/report/nanotechnology-medical-applications-global-market-hlc069b.html, accessed 4 May 2012.

25 G. Oberdörster, *J. Intern. Med.*, 2010, **267**, 89–105.

26 C. Medina, M. J. Santos-Martinez, A. Radomski, O. I. Corrigan and M. W. Radomski, *Br. J. Pharmacol.*, 2007, **150**, 552–558.

27 W. H. De Jong and P. J. Borm, *Int. J. Nanomed.*, 2008, **3**, 133–149.

28 P. J. A. Borm and D. Müller-Schulte, *Nanomedicine*, 2006, **1**, 235–249.

29 V. Murashov, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2009, **1**, 203–213.

30 A. Baun and S. F. Hansen, *Nanomedicine*, 2008, **3**, 605–608.

31 European Medicines Agency, *First International Workshop on Nanomedicine*, 2–3 September 2010, http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2009/12/event_detail_000095.jsp&mid=WC0b01ac058004d5c3, accessed 14 July 2012.

32 W. Sanchez, W. Sremski, B. Piccini, O. Palluel, E. Maillot-Maréchal, S. Betoulle, A. Jaffal, S. Aït-Aïssa, F. Brion, E. Thybaud, N. Hinfray and J.-M. Porcher, *Environ. Int.*, 2011, **37**, 1342–1348.

33 European Science Foundation, *ESF Forward Look on Nanomedicine 2005*, 2005, http://www.esf.org/publications/forward-looks.html, accessed 1 June 2012.

34 European Union, *Commission Recommendation of 18 October 2011 on the definition of nanomaterial*, http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ: L:2011:275:0038:0040:EN: PDF, accessed 10 July 2012.

35 I. Canton and G. Battaglia, *Chem. Soc. Rev.*, 2012, **41**, 2718–2739.

36 E. C. Dreaden, A. M. Alkilany, X. Huang, C. J. Murphy and M. A. El-Sayed, *Chem. Soc. Rev.*, 2012, **41**, 2740–2779.

37 B. Thiesen and A. Jordan, *Int. J. Hyperthermia*, 2008, **24**, 467–474.

38 C. G. Hadjipanayis, M. J. Bonder, S. Balakrishnan, X. Wang, H. Mao and G. C. Hadjipanayis, *Small*, 2008, **4**, 1925–1929.

39 V. P. Torchilin, *Nat. Rev. Drug Discovery*, 2005, **4**, 145–160.

40 C. Spuch and C. Navarro, *J. Drug Delivery*, 2011, 1–12.

41 B. Y. S. Kim, J. T. Rutka and W. C. W. Chan, *N. Engl. J. Med.*, 2010, **363**, 2434–2443.

42 J. Khandare, M. Calderon, N. M. Dagia and R. Haag, *Chem. Soc. Rev.*, 2012, **41**, 2824–2848.

43 D. Q. McNerny, P. R. Leroueil and J. R. Baker, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2010, **2**, 249–259.

44 S. Svenson, *Eur. J. Pharm. Biopharm.*, 2009, **71**, 445–462.

45 M. Elsabahy and K. L. Wooley, *Chem. Soc. Rev.*, 2012, **41**, 2545–2561.

46 J. H. Adair, M. P. Parette, E. I. Altinoglu and M. Kester, *ACS Nano*, 2010, **4**, 4967–4970.

47 R. A. Petros and J. M. DeSimone, *Nat. Rev. Drug Discovery*, 2010, **9**, 615–627.

48 J. W. Singer, *J. Controlled Release*, 2005, **109**, 120–126.

49 Y. Cu and W. M. Saltzman, *Nat. Mater.*, 2009, **8**, 11–13.

50 J. W. Singer, S. Shaffer, B. Baker, A. Bernareggi, S. Stromatt, D. Nienstedt and M. Besman, *Anti-Cancer Drugs*, 2005, **16**, 243–254.

51 S. Jevševar, M. Kunstelj and V. G. Porekar, *Biotechnol. J.*, 2010, **5**, 113–128.

52 R. Ionescu, Y. Broza, H. Shaltieli, D. Sadeh, Y. Zilberman, X. Feng, L. Glass-Marmor, I. Lejbkowicz, K. Müllen, A. Miller and H. Haick, *ACS Chem. Neurosci.*, 2011, **2**, 687–693.

53 http://clinicaltrials.gov/, *NCT01386203*, accessed 22 July 2012.

54 http://clinicaltrials.gov/, *NCT01420588*, accessed 22 July 2012.

55 http://clinicaltrials.gov/, *NCT01465087*, accessed 22 July 2012.

56 http://clinicaltrials.gov/, *NCT01292369*, accessed 22 July 2012.

57 http://clinicaltrials.gov/, *NCT00299598*, accessed 22 July 2012.

58 http://clinicaltrials.gov/, *NCT01007240*, accessed 22 July 2012.

59 http://clinicaltrials.gov/, *NCT01050777*, accessed 22 July 2012.

60 Celator Pharmaceuticals, *Products (CPX 351, CPX 1)*, http://www.celatorpharma.com/new/products.html, accessed 22 July 2012.

61 http://clinicaltrials.gov/, *NCT01416558*, accessed 22 July 2012.

62 http://clinicaltrials.gov/, *NCT00944801*, accessed 22 July 2012.

This journal is © The Royal Society of Chemistry 2013

Environ. Sci.: Processes Impacts, 2013, **15**, 123–144 | **139**

63 T. Barnes and R. Moots, *Int. J. Nanomed.*, 2007, **2**, 3–7.

64 http://clinicaltrials.gov/, *NCT01464593*, accessed 22 July 2012.

65 http://clinicaltrials.gov/, *NCT00093444*, accessed 22 July 2012.

66 http://clinicaltrials.gov/, *NCT01640847*, accessed 22 July 2012.

67 C. Oerlemans, W. Bult, M. Bos, G. Storm, J. F. Nijsen and W. E. Hennink, *Pharm. Res.*, 2010, **27**, 2569–2589.

68 NanoCarrier, *Product Pipeline*, http://www.nanocarrier. co.jp/en/research/pipeline/index.html, accessed 22 July 2012.

69 Veridex LLC, http://www.veridex.com/CellSearch/ CellSearchHCP.aspx, accessed 22 July 2012.

70 Nanosphere Inc., http://www.nanosphere.us/products, accessed 22 July 2012.

71 H. M. E. Azzazy and R. H. Christenson, *Clin. Biochem.*, 2002, **35**, 13–27.

72 Siemens Healthcare Diagnostics Inc., *Stratus® CS Acute Care™ Diagnostic System*, http://www.medical.siemens.com/ webapp/wcs/stores/servlet/ProductDisplay~q_catalogId~e_ -111~a_catTree~e_100001, 1023069, 1023067~a_langId~e_ -111~a_productId~e_182056~a_storeId~e_10001.htm, accessed 22 July 2012.

73 J. Lisziewicz, N. Bakare, S. A. Calarota, D. Bánhegyi, J. Szlávik, E. Újhelyi, E. R. Tőke, L. Molnár, Z. Lisziewicz, B. Autran and F. Lori, *PLoS One*, 2012, **7**, e35416.

74 D. Tyssen, S. A. Henderson, A. Johnson, J. Sterjovski, K. Moore, J. La, M. Zanin, S. Sonza, P. Karellas, M. P. Giannis, G. Krippner, S. Wesselingh, T. McCarthy, P. R. Gorry, P. A. Ramsland, R. Cone, J. R. A. Paull, G. R. Lewis and G. Tachedjian, *PLoS One*, 2010, **5**, e12309.

75 Starpharma Holdings Limited, http://www.starpharma. com/vivagel, accessed 22 July 2012.

76 Cytimmune Sciences Inc, http://www.cytimmune.com/ go.cfm?do=page.view&pid=26, accessed 22 July 2012.

77 Nanospectra Biosciences Inc., http:// www.nanospectra.com/index.html, accessed 22 July 2012.

78 http://clinicaltrials.gov/, *NCT00660543*, accessed 22 July 2012.

79 http://clinicaltrials.gov/, *NCT01296139*, accessed 22 July 2012.

80 Amag Pharmaceuticals Inc., *GastroMark™*, http://www. amagpharma.com/products/gastromark.php, accessed 22 July 2012.

81 Amag Pharmaceuticals Inc., *Feraheme*, http://www. feraheme.com/, accessed 10 June 2012.

82 Drugs@FDA, *Feromoxytol*, http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm.

83 http://clinicaltrials.gov/, *NCT01169935*, accessed 22 July 2012.

84 MagForce AG, http://www.magforce.de/en/produkte.html, accessed 22 July 2012.

85 Smith&Nephew, *ACTICOAT: Antimicrobial Barrier Dressing*, http://global.smith-nephew.com/us/ACTICOAT_PRODUCT_ RANGE_8803.htm, accessed 22 July 2012.

86 http://clinicaltrials.gov/, *NCT00659204*, accessed 22 July 2012.

87 http://clinicaltrials.gov/, *NCT01598480*, accessed 22 July 2012.

88 http://clinicaltrials.gov/, *NCT00337714*, accessed 22 July 2012.

89 J. E. Kim, J. Y. Shin and M. H. Cho, *Arch. Toxicol.*, 2012, **86**, 685–700.

90 A. Bumb, C. A. Regino, M. R. Perkins, M. Bernardo, M. Ogawa, L. Fugger, P. L. Choyke, P. J. Dobson and M. W. Brechbiel, *Nanotechnology*, 2010, **21**, 175704.

91 C. G. Daughton and T. A. Ternes, *Environ. Health Perspect.*, 1999, **107**(suppl. 6), 907–938.

92 A. B. Boxall, *EMBO Rep.*, 2004, **5**, 1110–1116.

93 M. J. M. Bueno, M. J. Gomez, S. Herrera, M. D. Hernando, A. Agüera and A. R. Fernández-Alba, *Environ. Pollut.*, 2012, **164**, 267–273.

94 S. González Alonso, M. Catalá, R. R. Maroto, J. L. R. Gil, Á. G. de Miguel and Y. Valcárcel, *Environ. Int.*, 2010, **36**, 195–201.

95 R. López-Roldán, M. L. de Alda, M. Gros, M. Petrovic, J. Martín-Alonso and D. Barceló, *Chemosphere*, 2010, **80**, 1337–1344.

96 T.-H. Fang, F.-H. Nan, T.-S. Chin and H.-M. Feng, *Mar. Pollut. Bull.*, 2012, **64**, 1435–1444.

97 Y. Yang, J. Fu, H. Peng, L. Hou, M. Liu and J. L. Zhou, *J. Hazard. Mater.*, 2011, **190**, 588–596.

98 P. Vazquez-Roig, R. Segarra, C. Blasco, V. Andreu and Y. Picó, *J. Chromatogr., A*, 2010, **1217**, 2471–2483.

99 T. Eggen, M. Moeder and A. Arukwe, *Sci. Total Environ.*, 2010, **408**, 5147–5157.

100 M. S. Fram and K. Belitz, *Sci. Total Environ.*, 2011, **409**, 3409–3417.

101 C. Wang, H. Shi, C. D. Adams, S. Gamagedara, I. Stayton, T. Timmons and Y. Ma, *Water Res.*, 2011, **45**, 1818–1828.

102 European Medicines Agency, *Guideline on the Environmental Risk Assessment of Medical Products for Human Use EMEA/CHMP/SWP/4447/00 corr 1**, Committee for Medicinal Products for Human Use, London, 2006, http://www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2009/10/WC500003978.pdf, accessed 10 June 2012.

103 A. J. Ramirez, R. A. Brain, S. Usenko, M. A. Mottaleb, J. G. O'Donnell, L. L. Stahl, J. B. Wathen, B. D. Snyder, J. L. Pitt, P. Perez-Hurtado, L. L. Dobbins, B. W. Brooks and C. K. Chambliss, *Environ. Toxicol. Chem.*, 2009, **28**, 2587–2597.

104 A. Lajeunesse, C. Gagnon, F. Gagné, S. Louis, P. Čejka and S. Sauvé, *Chemosphere*, 2011, **83**, 564–571.

105 L. H. Santos, A. N. Araujo, A. Fachini, A. Pena, C. Delerue-Matos and M. C. Montenegro, *J. Hazard. Mater.*, 2010, **175**, 45–95.

106 A. Daneshvar, J. Svanfelt, L. Kronberg, M. Prévost and G. A. Weyhenmeyer, *Chemosphere*, 2010, **80**, 301–309.

107 T. V. Madureira, J. C. Barreiro, M. J. Rocha, E. Rocha, Q. B. Cass and M. E. Tiritan, *Sci. Total Environ.*, 2010, **408**, 5513–5520.

108 A. Daneshvar, J. Svanfelt, L. Kronberg and G. A. Weyhenmeyer, *J. Environ. Monit.*, 2012, **14**, 596–603.

140 | *Environ. Sci.: Processes Impacts*, 2013, **15**, 123–144

This journal is © The Royal Society of Chemistry 2013

109 H. Leknes, I. E. Sturtzel and C. Dye, *Sci. Total Environ.*, 2012, **414**, 632–638.

110 S. Kugathas, R. J. Williams and J. P. Sumpter, *Environ. Int.*, 2012, **40**, 15–23.

111 V. L. Cunningham, V. J. D'Aco, D. Pfeiffer, P. D. Anderson, M. E. Buzby, R. E. Hannah, J. Jahnke and N. J. Parke, *Integr. Environ. Assess. Manage.*, 2012, **8**, 530–542.

112 N. Vieno, *Occurrence of Pharmaceuticals in Finnish Sewage Treatment Plants, Surface Waters, and Their Elimination in Drinking Water Treatment Processes*, Tampere University of Technology, 2007.

113 P. Verlicchi, M. Al Aukidy, A. Galletti, M. Petrovic and D. Barceló, *Sci. Total Environ.*, 2012, **430**, 109–118.

114 WHO/UNICEF, *Progress on Sanitation and Drinking-water: 2010*, 2010, http://www.who.int/water_sanitation_health/publications/9789241563956/en/index.html, accessed 21 July 2012.

115 European Environment Agency, *Urban waste water treatment (CSI 024) – Assessment published Dec 2010*, http://www.eea.europa.eu/data-and-maps/indicators/urban-waste-water-treatment/urban-waste-water-treatment-assessment-2/#toc-2, accessed 21 July 2012.

116 L. Wolf, C. Zwiener and M. Zemann, *Sci. Total Environ.*, 2012, **430**, 8–19.

117 S. Sauvé, K. Aboulfadl, S. Dorner, P. Payment, G. Deschamps and M. Prévost, *Chemosphere*, 2012, **86**, 118–123.

118 R. Owen and S. Jobling, *Nature*, 2012, **485**, 441.

119 P. Verlicchi, M. Al Aukidy and E. Zambello, *Sci. Total Environ.*, 2012, **429**, 123–155.

120 C. E. West and S. J. Rowland, *Environ. Sci. Technol.*, 2012, **46**, 4749–4756.

121 D. Fatta-Kassinos, M. I. Vasquez and K. Kümmerer, *Chemosphere*, 2011, **85**, 693–709.

122 A. Jelic, M. Gros, A. Ginebreda, R. Cespedes-Sánchez, F. Ventura, M. Petrovic and D. Barcelo, *Water Res.*, 2011, **45**, 1165–1176.

123 S. N. Mahnik, K. Lenz, N. Weissenbacher, R. M. Mader and M. Fuerhacker, *Chemosphere*, 2007, **66**, 30–37.

124 S. Jobling and R. Owen, Ethinyl oestradiol in the aquatic environment: a bitter pill for the precautionary principle, in *Late lessons from early warnings: science, precaution, innovation*, ed. D. Gee, European Environment Agency, Copenhagen, 2013, ch. 13, pp. 199–226.

125 M. C. Perron and P. Juneau, *Environ. Res.*, 2011, **111**, 520–529.

126 W. Zhang, M. Zhang, K. Lin, W. Sun, B. Xiong, M. Guo, X. Cui and R. Fu, *Environ. Toxicol. Pharmacol.*, 2012, **33**, 344–352.

127 S. Dietrich, F. Ploessl, F. Bracher and C. Laforsch, *Chemosphere*, 2010, **79**, 60–66.

128 J. C. Underwood, R. W. Harvey, D. W. Metge, D. A. Repert, L. K. Baumgartner, R. L. Smith, T. M. Roane and L. B. Barber, *Environ. Sci. Technol.*, 2011, **45**, 3096–3101.

129 Y. Guler and A. T. Ford, *Aquat. Toxicol.*, 2010, **99**, 397–404.

130 K. A. Kidd, P. J. Blanchfield, K. H. Mills, V. P. Palace, R. E. Evans, J. M. Lazorchak and R. W. Flick, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 8897–8901.

131 C. Vannini, G. Domingo, M. Marsoni, F. De Mattia, M. Labra, S. Castiglioni and M. Bracale, *Aquat. Toxicol.*, 2011, **101**, 459–465.

132 F. Pomati, C. Orlandi, M. Clerici, F. Luciani and E. Zuccato, *Toxicol. Sci.*, 2008, **102**, 129–137.

133 T. V. Madureira, M. J. Rocha, C. Cruzeiro, I. Rodrigues, R. A. Monteiro and E. Rocha, *Environ. Toxicol. Pharmacol.*, 2012, **34**, 34–45.

134 J. L. Oaks, M. Gilbert, M. Z. Virani, R. T. Watson, C. U. Meteyer, B. A. Rideout, H. L. Shivaprasad, S. Ahmed, M. J. Iqbal Chaudhry, M. Arshad, S. Mahmood, A. Ali and A. Ahmed Khan, *Nature*, 2004, **427**, 630–633.

135 ERAPharm, *Environmental Risk Assessment of Pharmaceuticals (EU Sixth Framework Programme)*, http://www.erapharm.org/, accessed 17 June 2012.

136 KNAPPE, *Knowledge and Need Assessment of Pharmaceutical Products in Environmental Waters: Project Final Report (2008)*, http://environmentalhealthcollaborative.org/images/KNAPPE_REPORT_FINAL.pdf, accessed 21 July 2012.

137 B. A. Boxall, M. A. Rudd, B. W. Brooks, D. J. Caldwell, K. Choi, S. Hickmann, E. Innes, K. Ostapyk, J. P. Staveley, T. Verslycke, G. T. Ankley, K. F. Beazley, S. E. Belanger, J. P. Berninger, P. Carriquiriborde, A. Coors, P. C. DeLeo, S. D. Dyer, J. F. Ericson, F. Gagné, J. P. Giesy, T. Gouin, L. Hallstrom, M. V. Karlsson, D. G. J. Larsson, J. M. Lazorchak, F. Mastrocco, A. McLaughlin, M. E. McMaster, R. D. Meyerhoff, R. Moore, J. L. Parrott, J. R. Snape, R. Murray-Smith, M. R. Servos, P. K. Sibley, J. O. Straub, N. D. Szabo, E. Topp, G. R. Tetreault, V. L. Trudeau and G. Van Der Kraak, *Environ. Health Perspect.*, 2012, **120**, 1221–1229.

138 E. R. Cooper, T. C. Siewicki and K. Phillips, *Sci. Total Environ.*, 2008, **398**, 26–33.

139 V. Roos, L. Gunnarsson, J. Fick, D. G. J. Larsson and C. Ruden, *Sci. Total Environ.*, 2012, **421**, 102–110.

140 A. Ginebreda, I. Muñoz, M. L. de Alda, R. Brix, J. López-Doval and D. Barceló, *Environ. Int.*, 2010, **36**, 153–162.

141 European Union, *Press Release (Environment and Water: Proposal to Reduce Water Pollution Risks)*, http://europa.eu/rapid/pressReleasesAction.do?reference=IP/12/88, accessed 29 July 2012.

142 W.-J. Sim, J.-W. Lee, E.-S. Lee, S.-K. Shin, S.-R. Hwang and J.-E. Oh, *Chemosphere*, 2011, **82**, 179–186.

143 R. Rodil, J. B. Quintana, E. Concha-Graña, P. López-Mahía, S. Muniategui-Lorenzo and D. Prada-Rodríguez, *Chemosphere*, 2012, **86**, 1040–1049.

144 C. Lacey, S. Basha, A. Morrissey and J. Tobin, *Environ. Monit. Assess.*, 2012, **184**, 1049–1062.

145 S. K. Behera, H. W. Kim, J.-E. Oh and H.-S. Park, *Sci. Total Environ.*, 2011, **409**, 4351–4360.

146 L. Shala and G. Foster, *Arch. Environ. Contam. Toxicol.*, 2010, **58**, 551–561.

147 K. Wille, H. Noppe, K. Verheyden, J. Vanden Bussche, E. De Wulf, P. Van Caeter, C. R. Janssen, H. F. De Brabander and L. Vanhaecke, *Anal. Bioanal. Chem.*, 2010, **397**, 1797–1808.

148 B. P. Chari and R. U. Halden, *Water Res.*, 2012, **46**, 4814–4824.

149 E. Gracia-Lor, J. V. Sancho, R. Serrano and F. Hernández, *Chemosphere*, 2012, **87**, 453–462.

150 Y. Fang, A. Karnjanapiboonwong, D. A. Chase, J. F. Wang, A. N. Morse and T. A. Anderson, *Environ. Toxicol. Chem.*, 2012, **31**, 550–555.

151 V. Kumar, N. Nakada, M. Yasojima, N. Yamashita, A. C. Johnson and H. Tanaka, *Chemosphere*, 2011, **82**, 1124–1128.

152 E. Vulliet, L. Wiest, R. Baudot and M.-F. Grenier-Loustalot, *J. Chromatogr., A*, 2008, **1210**, 84–91.

153 J. Shen, Y. Zhu, X. Yang and C. Li, *Chem. Commun.*, 2012, **48**, 3686–3699.

154 J. Yin, B. Shao, J. Zhang and K. Li, *Bull. Environ. Contam. Toxicol.*, 2010, **84**, 39–45.

155 L. Kovalova, C. S. McArdell and J. Hollender, *J. Chromatogr., A*, 2009, **1216**, 1100–1108.

156 J.-U. Mullot, S. Karolak, A. Fontova, B. Huart and Y. Levi, *Anal. Bioanal. Chem.*, 2009, **394**, 2203–2212.

157 C. M. Coetsier, S. Spinelli, L. Lin, B. Roig and E. Touraud, *Environ. Int.*, 2009, **35**, 787–792.

158 J. C. Van De Steene, C. P. Stove and W. E. Lambert, *Sci. Total Environ.*, 2010, **408**, 3448–3453.

159 Y. Vystavna, F. Huneau, V. Grynenko, Y. Vergeles, H. Celle-Jeanton, N. Tapie, H. Budzinski and P. Le Coustumer, *Water, Air, Soil Pollut.*, 2012, **223**, 2111–2124.

160 M. Stuart, D. Lapworth, E. Crane and A. Hart, *Sci. Total Environ.*, 2012, **416**, 1–21.

161 J.-P. Besse, J.-F. Latour and J. Garric, *Environ. Int.*, 2012, **39**, 73–86.

162 J. O. Straub, *Integr. Environ. Assess. Manage.*, 2010, **6**, 540–566.

163 V. Calisto and V. I. Esteves, *Chemosphere*, 2009, **77**, 1257–1274.

164 European Union, *Nanotechnology (CORDIS Archieves)*, ftp://ftp.cordis.europa.eu/pub/nanotechnology/docs/fp7_call_2007_nano.pdf, accessed 14 July 2014.

165 A. D. Maynard, P. A. Baron, M. Foley, A. A. Shvedova, E. R. Kisin and V. Castranova, *J. Toxicol. Environ. Health, Part A*, 2004, **67**, 87–107.

166 M. A. Kiser, P. Westerhoff, T. Benn, Y. Wang, J. Perez-Rivera and K. Hristovski, *Environ. Sci. Technol.*, 2009, **43**, 6757–6763.

167 S. A. Blaser, M. Scheringer, M. MacLeod and K. Hungerbühler, *Sci. Total Environ.*, 2008, **390**, 396–409.

168 F. Gottschalk, T. Sonderer, R. W. Scholz and B. Nowack, *Environ. Sci. Technol.*, 2009, **43**, 9216–9222.

169 Y. Hong, R. J. Honda, N. V. Myung and S. L. Walker, *Environ. Sci. Technol.*, 2009, **43**, 8834–8839.

170 G. V. Lowry, K. B. Gregory, S. C. Apte and J. R. Lead, *Environ. Sci. Technol.*, 2012, **46**, 6893–6899.

171 S. A. Cumberland and J. R. Lead, *J. Chromatogr., A*, 2009, **1216**, 9099–9105.

172 S. S. Khan, A. Mukherjee and N. Chandrasekaran, *Water Res.*, 2011, **45**, 5184–5190.

173 Z. Sheng and Y. Liu, *Water Res.*, 2011, **45**, 6039–6050.

174 J. Fabrega, S. R. Fawcett, J. C. Renshaw and J. R. Lead, *Environ. Sci. Technol.*, 2009, **43**, 7285–7290.

175 J. Fabrega, J. C. Renshaw and J. R. Lead, *Environ. Sci. Technol.*, 2009, **43**, 9004–9009.

176 Z. Q. Li, K. Greden, P. J. J. Alvarez, K. B. Gregory and G. V. Lowry, *Environ. Sci. Technol.*, 2010, **44**, 3462–3467.

177 J. Gao, K. Powers, Y. Wang, H. Zhou, S. M. Roberts, B. M. Moudgil, B. Koopman and D. S. Barber, *Chemosphere*, 2012, **89**, 96–101.

178 H. Zhang, J. A. Smith and V. Oyanedel-Craver, *Water Res.*, 2012, **46**, 691–699.

179 A. Hitchman, Y. Ju-Nam, G. Sambrook-Smith, G. M. Sterling and J. R. Lead, *Chemosphere*, 2012, DOI: 10.1016/j.chemosphere.2012.07.041.

180 C. Coutris, E. J. Joner and D. H. Oughton, *Sci. Total Environ.*, 2012, **420**, 327–333.

181 H. Schwegmann, A. J. Feitz and F. H. Frimmel, *J. Colloid Interface Sci.*, 2010, **347**, 43–48.

182 S. Lee, K. Kim, H. K. Shon, S. D. Kim and J. Cho, *J. Nanopart. Res.*, 2011, **13**, 3051–3061.

183 A. A. Keller, H. Wang, D. Zhou, H. S. Lenihan, G. Cherr, B. J. Cardinale, R. Miller and Z. Ji, *Environ. Sci. Technol.*, 2010, **44**, 1962–1967.

184 J. Fabrega, S. N. Luoma, C. R. Tyler, T. S. Galloway and J. R. Lead, *Environ. Int.*, 2011, **37**, 517–531.

185 R. Handy, F. von der Kammer, J. R. Lead, M. Hassellöv, R. Owen and M. Crane, *Ecotoxicology*, 2008, **17**, 287–314.

186 Y. Ju-Nam and J. R. Lead, *Sci. Total Environ.*, 2008, **400**, 396–414.

187 S. J. Klaine, P. J. J. Alvarez, G. E. Batley, T. F. Fernandes, R. D. Handy, D. Y. Lyon, S. Mahendra, M. J. McLaughlin and J. R. Lead, *Environ. Toxicol. Chem.*, 2008, **27**, 1825–1851.

188 A. M. El Badawy, R. G. Silva, B. Morris, K. G. Scheckel, M. T. Suidan and T. M. Tolaymat, *Environ. Sci. Technol.*, 2010, **45**, 283–287.

189 S. C. Hayden, G. X. Zhao, K. Saha, R. L. Phillips, X. N. Li, O. R. Miranda, V. M. Rotello, M. A. El-Sayed, I. Schmidt-Krey and U. H. F. Bunz, *J. Am. Chem. Soc.*, 2012, **134**, 6920–6923.

190 J. L. Ferry, P. Craig, C. Hexel, P. Sisco, R. Frey, P. L. Pennington, M. H. Fulton, I. G. Scott, A. W. Decho, S. Kashiwada, C. J. Murphy and T. J. Shaw, *Nat. Nanotechnol.*, 2009, **4**, 441–444.

191 M.-N. l. Croteau, S. K. Misra, S. N. Luoma and E. Valsami-Jones, *Environ. Sci. Technol.*, 2011, **45**, 6600–6607.

192 J. B. Morrow, C. P. Arango and R. D. Holbrook, *J. Environ. Qual.*, 2010, **39**, 1934.

193 A. R. Stojak, T. Raftery, S. J. Klaine and T. L. Mcnealy, *Nanotoxicology*, 2011, **5**, 730–742.

194 M. S. Hull, P. Chaurand, J. Rose, M. Auffan, J.-Y. Bottero, J. C. Jones, I. R. Schultz and P. J. Vikesland, *Environ. Sci. Technol.*, 2011, **45**, 6592–6599.

195 M. O. Montes, S. K. Hanna, H. S. Lenihan and A. A. Keller, *J. Hazard. Mater.*, 2012, **225–226**, 139–145.

196 A. Baun, S. N. Sørensen, R. F. Rasmussen, N. B. Hartmann and C. B. Koch, *Aquat. Toxicol.*, 2008, **86**, 379–387.

197 J. W. Park, T. B. Henry, S. Ard, F. M. Menn, R. N. Compton and G. S. Sayler, *Nanotoxicology*, 2011, **5**, 406–416.

198 D. Zhang, H. Niu, X. Zhang, Z. Meng and Y. Cai, *J. Hazard. Mater.*, 2011, **192**, 1088–1093.

199 T. Walser, L. K. Limbach, R. Brogioli, E. Erismann, L. Flamigni, B. Hattendorf, M. Juchli, F. Krumeich, C. Ludwig, K. Prikopsky, M. Rossier, D. Saner, A. Sigg, S. Hellweg, D. Gunther and W. J. Stark, *Nat. Nanotechnol.*, 2012, **7**(8), 520–524.

200 L. Roes, M. K. Patel, E. Worrell and C. Ludwig, *Sci. Total Environ.*, 2012, **417**, 76–86.

201 D. R. Taft, in *Pharmacology: Principles and Practice*, ed. M. P. Hacker, W. S. Messer and K. A. Bachmann, Academic Press/Elsevier, 2009, pp. 176–200.

202 J. Lipka, M. Semmler-Behnke, R. A. Sperling, A. Wenk, S. Takenaka, C. Schleh, T. Kissel, W. J. Parak and W. G. Kreyling, *Biomaterials*, 2010, **31**, 6574–6581.

203 S. K. Balasubramanian, J. Jittiwat, J. Manikandan, C.-N. Ong, L. E. Yu and W.-Y. Ong, *Biomaterials*, 2010, **31**, 2034–2042.

204 S. Hirn, M. Semmler-Behnke, C. Schleh, A. Wenk, J. Lipka, M. Schäffler, S. Takenaka, W. Möller, G. Schmid, U. Simon and W. G. Kreyling, *Eur. J. Pharm. Biopharm.*, 2011, **77**, 407–416.

205 V. Ferranti, C. Chabenat, H. Marchais, S. Menager, H. Hue, A. M. Orecchioni and O. Lafont, *Drug Metab. Drug Interact.*, 2001, **18**, 191–208.

206 V. L. Elliott, G. T. Edge, M. M. Phelan, L.-Y. Lian, R. Webster, R. F. Finn, B. K. Park and N. R. Kitteringham, *Mol. Pharmaceutics*, 2012, **9**, 1291–1301.

207 Drugs@FDA, *Taxol*, http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf, accessed 10 May 2012.

208 Drugs@FDA, *Abraxane*, http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021660s025s026s029lbl.pdf, accessed 10 May 2012.

209 H. P. Jarvie, H. Al-Obaidi, S. M. King, M. J. Bowes, M. J. Lawrence, A. F. Drake, M. A. Green and P. J. Dobson, *Environ. Sci. Technol.*, 2009, **43**, 8622–8628.

210 T. L. Kirschling, P. L. Golas, J. M. Unrine, K. Matyjaszewski, K. B. Gregory, G. V. Lowry and R. D. Tilton, *Environ. Sci. Technol.*, 2011, **45**, 5253–5259.

211 M. Zhang and M. Akbulut, *Langmuir*, 2011, **27**, 12550–12559.

212 J.-M. Nam, C. S. Thaxton and C. A. Mirkin, *Science*, 2003, **301**, 1884–1886.

213 J. Robbens, C. Vanparys, I. Nobels, R. Blust, K. Van Hoecke, C. Janssen, K. De Schamphelaere, K. Roland, G. Blanchard, F. Silvestre, V. Gillardin, P. Kestemont, R. Anthonissen, O. Toussaint, S. Vankoningsloo, C. Saout, E. Alfaro-Moreno, P. Hoet, L. Gonzalez, P. Dubruel and P. Troisfontaines, *Toxicology*, 2010, **269**, 170–181.

214 T. C. K. Heiden, E. Dengler, W. J. Kao, W. Heideman and R. E. Peterson, *Toxicol. Appl. Pharmacol.*, 2007, **225**, 70–79.

215 A. N. Petit, P. Eullaffroy, T. Debenest and F. Gagne, *Aquat. Toxicol.*, 2010, **100**, 187–193.

216 A. N. Petit, T. Debenest, P. Eullaffroy and F. Gagne, *Nanotoxicology*, 2012, **6**, 315–326.

217 I. J. Suarez, R. Rosal, A. Rodriguez, A. Ucles, A. R. Fernandez-Alba, M. D. Hernando and E. García-Calvo, *TrAC, Trends Anal. Chem.*, 2011, **30**, 492–506.

218 H. Zhu, J. Han, J. Q. Xiao and Y. Jin, *J. Environ. Monit.*, 2008, **10**, 713–717.

219 H. Wang, X. Kou, Z. Pei, J. Q. Xiao, X. Shan and B. Xing, *Nanotoxicology*, 2011, **5**, 30–42.

220 J. Hu, D. Wang, J. Wang and J. Wang, *Environ. Pollut.*, 2012, **162**, 216–222.

221 V. Shah and I. Belozerova, *Water, Air, Soil Pollut.*, 2009, **197**, 143–148.

222 T. Sabo-Attwood, J. M. Unrine, J. W. Stone, C. J. Murphy, S. Ghoshroy, D. Blom, P. M. Bertsch and L. A. Newman, *Nanotoxicology*, 2012, **6**, 353–360.

223 J. D. Judy, J. M. Unrine, W. Rao, S. Wirick and P. M. Bertsch, *Environ. Sci. Technol.*, 2012, **46**(15), 8467–8474.

224 R. Barrena, E. Casals, J. Colón, X. Font, A. Sánchez and V. Puntes, *Chemosphere*, 2009, **75**, 850–857.

225 P. V. Asharani, Y. lianwu, Z. Gong and S. Valiyaveettil, *Nanotoxicology*, 2011, **5**, 43–54.

226 B. Geffroy, C. Ladhar, S. Cambier, M. Treguer-Delapierre, D. Brethes and J. P. Bourdineaud, *Nanotoxicology*, 2012, **6**, 144–160.

227 P. P. Pompa, G. Vecchio, A. Galeone, V. Brunetti, S. Sabella, G. Maiorano, A. Falqui, G. Bertoni and R. Cingolani, *Nano Res.*, 2011, **4**, 405–413.

228 G. Vecchio, A. Galeone, V. Brunetti, G. Maiorano, L. Rizzello, S. Sabella, R. Cingolani and P. P. Pompa, *Nanomed.: Nanotechnol., Biol. Med.*, 2012, **8**, 1–7.

229 S. Tedesco, H. Doyle, J. Blasco, G. Redmond and D. Sheehan, *Aquat. Toxicol.*, 2010, **100**, 178–186.

230 O. V. Tsyusko, J. M. Unrine, D. Spurgeon, E. Blalock, D. Starnes, M. Tseng, G. Joice and P. M. Bertsch, *Environ. Sci. Technol.*, 2012, **46**, 4115–4124.

231 V. Christen and K. Fent, *Chemosphere*, 2012, **87**, 423–434.

232 C. Wei, Y. Zhang, J. Guo, B. Han, X. Yang and J. Yuan, *J. Environ. Sci.*, 2010, **22**, 155–160.

233 K. Van Hoecke, K. A. C. De Schamphelaere, P. Van der Meeren, S. Lcucas and C. R. Janssen, *Environ. Toxicol. Chem.*, 2008, **27**, 1948–1957.

234 European Medicines Agency, *Orphan Medical Product Designation*, http://www.ema.europa.eu/docs/en_GB/document_library/Brochure/2011/03/WC500104234.pdf, accessed 4 May 2012.

235 D. B. Kramer, S. Xu and A. S. Kesselheim, *N. Engl. J. Med.*, 2012, **366**, 848–855.

236 B. H. Robinson, *Sci. Total Environ.*, 2009, **408**, 183–191.

237 European Union, *Directive 2012/19/EU of the European Parliament and of the Council of 4 July 2012 on waste electrical and electronic equipment (WEEE)*, accessed 17 November 2012.

238 E. J. Petersen, Q. Huang and W. J. Weber, *Environ. Toxicol. Chem.*, 2010, **29**, 1106–1112.

239 W. Giger, A. C. Alder, E. M. Golet, H.-P. E. Kohler, C. S. McArdell, E. Molnar, H. Siegrist and M. J.-F. Suter, *Chimia*, 2003, **57**, 485–491.

240 F. Stuer-Lauridsen, M. Birkved, L. P. Hansen, H. C. Holten Lützhøft and B. Halling-Sørensen, *Chemosphere*, 2000, **40**, 783–793.

241 E. Walters, K. McClellan and R. U. Halden, *Water Res.*, 2010, **44**, 6011–6020.

242 J. Giri, M. S. Diallo, W. A. G. Iii, N. F. Dalleska, X. Fang and Y. Tang, *Environ. Sci. Technol.*, 2009, **43**, 5123–5129.

243 R. D. Handy, G. Cornelis, T. Fernandes, O. Tsyusko, A. Decho, T. Sabo-Attwood, C. Metcalfe, J. A. Steevens, S. J. Klaine, A. A. Koelmans and N. Horne, *Environ. Toxicol. Chem.*, 2012, **31**, 15–31.

244 K. Malkiewicz, M. Pettitt, K. A. Dawson, A. Toikka, S. O. Hansson, J. Hukkinen, I. Lynch and J. Lead, *Nanomaterials in REACH*, 2011, http://www.skep-network.eu/Libraries/Network_documents/SKEP_Nanomaterials_in_REACH_Report.sflb.ashx, accessed 10 June 2012.

245 I. Römer, T. A. White, M. Baalousha, K. Chipman, M. R. Viant and J. R. Lead, *J. Chromatogr., A*, 2011, **1218**, 4226–4233.

246 P. C. Naha, M. Davoren, A. Casey and H. J. Byrne, *Environ. Sci. Technol.*, 2009, **43**, 6864–6869.

247 M. Tejamaya, I. Römer, R. C. Merrifield and J. R. Lead, *Environ. Sci. Technol.*, 2012, **46**, 7011–7017.